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 Abstract 
 
Heart disease remains the number one killer of Americans.  Patient’s high cholesterol 
numbers are a major risk factor for the development of heart disease.  Studies performed 
by the Centers for Disease Control (CDC) and the U.S. Department of Health and Human 
Services (DHHS) have recognized this as an area in need of improvement.  Strategies for 
improvement of patients’ serum cholesterol and adherence to the recommended therapies 
have been explored.  The purpose of this evidence based project is to compare cholesterol 
management outcomes in patients cared for by a nurse practitioner, with lipid 
management certification, to patients cared for by their usual providers, in a population 
with severe hypercholesterolemia.  The population samples, non-pregnant adults, aged 20 
years old or greater, will be obtained from patients with a minimum baseline low density 
lipoprotein cholesterol (LDL-C) of >190.  Levels will be accessed through an electronic 
health record database, on blood work previously ordered by a network provider.  All 
patients in both groups will receive the same standard care available.  The difference will 
be the provider only; the nurse practitioner holds a certification in lipid management.  
Data analysis will be on the percent change in LDL-C, from baseline at 4 to 12 weeks, as 
well as provider adherence to the guidelines. The benefit of this investigation is that it 
may demonstrate a successful treatment strategy for the management of high cholesterol. 
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Chapter One: Introduction and Overview of the Problem of Interest 
Sixty-seven years ago, the Framingham Heart Study (FHS), a prospective  
cohort trial, set in Framingham, Massachusetts, was established initially as a 20 year 
epidemiological investigation to evaluate heart disease.  The study continues today, as an 
Offspring cohort as well as a Third Generation cohort, and includes an examination of the 
role of genetics.  Analyses over the years have disclosed hypertension and high 
cholesterol among the risk factors for the development of atherosclerotic cardiovascular 
disease (ASCVD) in both men and women, and not simply a normal phenomenon of 
aging (Castelli, Anderson, Wilson, & Levy, 1992; Mahmood, Levy, Vasan, & Wang, 
2014).  Critics however, note that the Framingham study investigated a population of 
Caucasians and question its generalizability. 
The INTERHEART study investigators, in contrast, sought to examine 
cardiovascular risk factors across varied ethnic groups and geographic areas.  This 
investigation was a large international case control study, which demonstrated that 
smoking and abnormal lipids were the two strongest modifiable predictors of  myocardial 
infarct (MI) in men and women and across all ethnic and geographic regions (Yussuf et 
al., 2004).     
As heart disease globally remains the leading cause of death, (World Health 
Organization, 2015), it is recognized that one out of three people have cardiovascular 
disease (CDC, 2014).   The American Heart Association (AHA) has identified an ideal 
total cholesterol level to be <200 mg/dL.  The National Health and Nutrition Examination 
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Survey (NHANES) data from 2011 to 2012 demonstrated that only 46% of adults met 
that criteria (Mozaffarin, et al., 2015).  
The AHA has identified metrics of health for varied cholesterol levels.  An ideal 
TC level is <200 mg/dL, intermediate: 200-239 mg/dL, and poor: >240 mg/dL 
(Mozaffarian et al., 2015).  The prevalence of high cholesterol remains relatively high.  
The “percent of adults age 20 years and over with high serum total cholesterol (greater 
than or equal to 240 mg/dL): 13.4% (2009-2012)”, while the “mean serum total 
cholesterol level for adults age 20 years and over: 196 mg/dL (2009-2012)” (Centers for 
Disease Control, 2014a, FastStats Cholesterol).  Further, “the mean level of LDL 
cholesterol for American adults > 20 years of age was 115.8 mg/dL in 2009 to 2012” 
(Mozaffarin et al., 2015, p.e108). 
 Despite the high prevalence, screening efforts to identify those at risk and in need 
of treatment, remains inadequate.  According to the Centers for Disease Control (CDC) 
(2014b), the 2010 National Ambulatory Medical Care Survey (NAMCS) reported that 
only 15.7% of office visits were recorded in the medical record for hyperlipidemia and 
only 7.8% of the office visits were for diagnostic and screening purposes for blood lipids 
that were either ordered or provided.  The AHA has outlined policy solutions for 
improvement, including ensuring national guideline use to increase adherence 
(Mozaffarian et al., 2015).  Federally, they recommend exploring prospects to assimilate 
mobile technologies and applications to improve outcomes (Mozaffarian et al., 2015).   
Therefore, there is room for improvement in the management of patients’ serum 
cholesterol levels.  The World Health Organization (2015), as well as the AHA, 
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(Mozaffarian et al., 2015) identify two levels of intervention: population-wide, and 
individually-focused.  Ideally, these levels of intervention should be enmeshed to 
optimize outcomes.  The World Health Organization suggests that individual, targeted 
therapy be employed to those with the highest risk, and in the most cost-efficient manner, 
including care with “non-physician health workers” (World Health Organization, 2015, 
How can the burden of cardiovascular diseases be reduced?).  
Background 
Recently, the American College of Cardiology (ACC) and the American Heart 
Association (AHA) released the 2013 ACC/AHA Guideline on the Treatment of Blood 
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Stone et al., 2014).  
The guideline is based on randomized controlled trials (RCT), meta-analyses, and high 
quality observational studies only (Stone et al., 2014).    
According to the authors, the purpose of the guideline is to disseminate a tool for 
ASCVD population risk reduction, and is not intended as a guide for the management of 
complex lipid disorders as “it is anticipated that clinicians with lipid expertise can 
contribute to their management” (Stone et al., 2014, p. 10).  However, it is conveyed that 
four groups of patients would benefit from statin therapy, one of which is people with 
“primary elevations of LDL-C >190 mg/dL” (Stone et al., 2014, p.13).   Notably, with 
respect to individuals with severe LDL-C (> 190 mg/dL), the Blood Cholesterol 
Guidelines indicate the following:  
The guideline recognizes that adults ≥21 years of age with primary, severe 
elevations of LDL–C (≥190 mg/dL) have a high lifetime risk for ASCVD events.  
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This is due to their lifetime exposure to markedly elevated LDL–C levels arising 
from genetic causes.  Thus, at age 21, these individuals should receive statin 
therapy if they have not already been diagnosed and treated before this age.   
Although in most clinical trials, individuals with LDL–C ≥190 mg/dL were not 
included due to their need for treatment, extensive evidence shows that each 39 
mg/dL reduction in LDL–C by statin therapy reduces ASCVD risk by about 20% 
(Stone et al., 2014, p. 28).  
Familial hypercholesterolemia (FH) is “the most common dominantly inherited 
disorder in humans” (Watts et al., 2014, p. 153), with a genetic mutation of lipid 
metabolism, causing severe elevations of LDL cholesterol, that if left untreated, can lead 
to premature death from cardiovascular disease.   The problem is underdiagnosed and 
undertreated: “There are probably more than 15 million people with FH worldwide, but 
less than 10% have been detected and only 5% adequately treated” (Watts et al., 2014, 
p.153).  Further, “without treatment, more than half of all men with FH and 30% of 
women with FH are expected to have a myocardial infarction before 60 years of 
age”(Goldberg et al., 2011b, p.48).  
  Generally, two forms of FH exist:  homozygous FH, which carries an incidence of 
1 in one million and heterozygous FH, which carries an incidence of about 1 in every 300 
to 500 people and is more common than type 1 diabetes or cystic fibrosis (Defesche, 
2010).  FH can be due to a defective LDL receptor, defective apolipoprotein B-100, or 
mutations in the pro-protein convertase subtilitsin/kexin type 9 (PCSK9) gene (Goldberg 
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et al., 2011a).  Heterozygous FH is determined when the mutation is inherited from one 
parent.      
FH is defined as having an LDL-C > 190 (Third Report of the National 
Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults, 2002).  In addition, according to the International FH 
Foundation, “a plasma LDL cholesterol of 5.0mmol/dL or greater indicates high 
probability of FH in the absence of a positive parental history of hypercholesterolemia or 
premature CHD” (Watts, 2014, p.150).  (Utilizing the conversion factor of x mg/dL 
cholesterol = x mmol x 38.7; 193.5mg/dL = 5.0 mmol, Watts et al., 2014).  This is a 
clinically relevant point for population screening.  
The focus of this evidence based practice (EBP) project will be on probable 
heterozygous FH, in populations with an LDL-C > 190.   Specifically, “heterozygous 
familial hypercholesterolemia (FH) is a dominantly inherited disorder caused by 
mutations of the low-density lipoprotein (LDL) receptor locus on the short arm of 
chromosome 19” (Williams et al., 1993, p. 171).  Traditionally, there have been three 
well known diagnostic tools to help clinicians make a diagnosis of FH –the Dutch Lipid 
Clinic Network Diagnostic Criteria (DLCN), the U.S. Make Early Diagnosis Prevent 
Early Death (MED PED) criteria, and the Simon Broome Register Diagnostic Criteria  
(Willard, 2011).  These methods combine criteria, physical findings, family history and 
genetic testing. Based on these criteria, often one could be placed in categories of 
definite, probable, or possible FH.  However, the more current literature identifies FH  
categorically as those with an LDL-C > 190 (Stone et al., 2014; Third Report of the 
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National Cholesterol Education Program Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults, 2002; Watts et al., 2014).   
Heterozygous FH (HeFH) patients have LDL cholesterol levels often twice 
normal with an increased cardiovascular risk for atherosclerosis (Williams et al., 1993).  
This heightened risk is due to prolonged elevations in cholesterol levels, since birth.  It is 
commonly associated with physical findings of the skin such as tendon xanthomas, 
xanthelasmas, or a premature corneal arcus, however, the physical findings may not 
always be present.  Genetic testing may be performed, however, it is expensive, not 
always available, and is unnecessary, as elevated lipids can be categorical, physical exam 
findings and a positive family history (Goldberg et al., 2011a).  Further, it is unclear how 
health insurance companies may view genetic testing results that disclose a criterion that 
is associated with premature morbidity and mortality.   
Significance to health care, financing, and advance nursing practice 
High quality scientific trials have demonstrated a clear benefit of statin therapy in 
the primary and secondary prevention of ASCVD (Stone et al., 2014).  It has been noted 
however that there has been a dearth of literature reporting the social and economic value 
of statin therapy.  Grabowksi et al. (2012) explored the social value of statins on a 
population level, within the U.S.  Social value weighs the total cost of treatments to the 
cost of the disease, from a societal and economic perspective.  Investigators reported that: 
National survey data suggest that statin therapy reduced low-density lipoprotein 
levels by 18.8 percent, which translated into roughly 40,000 fewer deaths, 60,000 
fewer hospitalizations for heart attacks, and 22,000 fewer hospitalizations for 
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strokes in 2008.  For people starting statin therapy in 1987–2008, consumers 
captured $947.4 billion (76 percent) of the total social value of the survival gains 
(Grabowski et al., 2012, p. 2276). 
While progress has been made, the authors note that if all identified patients eligible to be 
on statin therapy were treated as per the guidelines, additional societal gains might be 
demonstrated.  
 Further benefits can be made from a population perspective, if identified patients 
were treated.  According to data from 2009-2012 presented by the AHA, “ >100 million 
US adults > 20 years of age have total cholesterol levels > 200 mg/dL; almost 31 million 
have levels > 240mg/dL” (Mozaffarian et al., 2015, p.e32).   The U.S. Department of 
Health and Human Services (U.S.DHHS) has identified population wide goals for 2020, 
titled Healthy People 2020 (HP2020).  An objective of the agency is to “improve 
cardiovascular health and quality of life through prevention, detection, and treatment of 
risk factors for heart attack and stroke; early identification and treatment of heart attacks 
and strokes; and prevention of repeat cardiovascular events” (U.S. DHHS, 2015, Goals).    
Astoundingly, the expenses of heart disease and stroke combined, cost the country 
more than $320 billion, in 2011, including direct and indirect costs (Mozaffarian et al., 
2015).  The cost of cardiovascular disease remains higher than any other diagnostic group 
(Mozaffarian et al., 2015).  
 Therefore, in light of the high incidence of cardiovascular disease with known 
modifiable risk factors, and the continued high prevalence of undertreated elevated 
cholesterol levels, much work is yet to be done to improve the health status of 
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individuals.  The current methods of management are unsatisfactory.  One can turn to an 
EBP change for amelioration. 
 Melnyk and Fineout-Overholt (2010) describe EBP as clinical practice occurring 
within the context of external evidence from research, expert opinion leaders, and 
evidence based theory as well as clinical expertise and patient preferences.  The purposes 
of EBP are multifold: high quality, cost-effective care, improved outcomes, and clinician 
satisfaction (Melnyk & Fineout-Overholt, 2010).   It is within the mission of the 
development of EBP that the following clinical question is derived. 
Question Guiding Inquiry: PICO-T 
The clinical question is displayed in a PICO-T format (Patient Population,   
Issue of Interest, Comparison group, Outcome and Timeframe).  The PICO-T question 
developed in the setting of patients with high cholesterol is:  In non-pregnant adults aged 
20 years old or greater, with a diagnosis of probable heterozygous familial 
hypercholesterolemia, would treatment in a lipid clinic by a nurse practitioner certified in 
lipid management, compared to usual care, lead to an improvement in the LDL 
cholesterol at the end of a 3 month period?  Usual care references treatment by any 
provider, including primary care, or cardiology, that is not certified in lipid management.  
Lipid Certification 
A clinical lipid specialist (CLS) is a clinician who holds an advanced certification 
in the field of lipidology as conferred by the Accreditation Council for Clinical 
Lipidology (ACCL, 2015a).  Traditionally, the certification was open to professionals 
such as nurses, nurse practitioners (NPs), physician assistants (PAs), dieticians, exercise 
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physiologists, and pharmacists, who were board eligible based on the satisfaction of 
specified rigorous academic, clinical and educational requirements (ACCL, 2015b).   
Recently, eligibility has been expanded to physicians.  Generally, most physicians are 
certified by the American Board of Clinical Lipidology (ABCL) and are called 
lipidologists upon successful exam completion.  Lipid certification demonstrates one’s 
credibility to the discipline and serves as a benchmark of competency.  
System and Population Impact 
For the reasons outlined, national as well as international goals for improvement 
of patients’ blood cholesterol and the improvement of cardiovascular risk factors have 
been established.  The CDC has identified a national goal to prevent one million heart 
attacks and strokes by the year 2017 (CDC, 2014a) while the U.S. DHHS has specifically 
established HP2020 goals for the management of cholesterol (U.S. DHHS, 2015).  These 
include Heart Disease and Stroke Goal 13 (HDS-13), to: “increase the proportion of 
adults with elevated LDL cholesterol who have been advised by a heath care provider 
regarding cholesterol-lowering management, including lifestyle changes and, if indicated, 
medication” and HDS-14, to “increase the proportion of adults with elevated LDL-
cholesterol who adhere to the prescribed LDL-cholesterol lowering management lifestyle 
changes, and, if indicated, medication” (U.S. DHHS, 2015, Heart Disease and Stroke 
Objectives).  Similarly, the AHA has established a goal of reducing CVD mortality by 
20% by 2020 (Mozaffarian et al., 2015).  Therefore, in summary, an emphasis on 
advisement and adherence to treatment of LDL-cholesterol, is recommended.  
Internationally, the WHO established a global non-communicable disease target that “at 
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least 50% of eligible people should receive drug therapy and counseling (including 
glycaemic control) to prevent heart attacks and strokes” between 2013-2020 (World 
Health Organization, 2015,WHO Response).  
Purpose, Aims, Objectives 
The purpose of this EBP is to describe a successful treatment strategy, designed to 
reflect a modern care model, by a nurse practitioner (NP) practicing within a lipid clinic, 
to treat patients with excessively high cholesterol levels.  The model, of an advanced 
practice nurse caring for patients with risk factors for chronic disease, is consistent with 
the model of team-based care, as supported by the ACC (Brindis, Rodgers, & Handberg, 
2011).  Barriers, such as adherence to recommended treatments, have been 
acknowledged, and remain a challenge to overcome.  
Further, in team-based care, there is effective utilization of resources, where 
physicians can provide complex tasks that require medical training.  This model is 
consistent with Bauer’s observation (2010) that nurse practitioners have been 
underutilized resources for healthcare reform.  The proposed model exemplifies the 
economic principle of input substitution where cost effective, quality care can be 
provided (or substituted) by an alternative means than traditional approaches.  This is 
defined further: “It is the cost of different labor inputs for producing the same service” 
(Bauer, 2012, p.230).  
In addition, this model of an EBP will demonstrate linkage to all of the Eight 
Essentials of Doctoral Nursing Practice (American Association of Colleges of Nursing, 
2006).  It will also meet the competencies for improved clinical education as a part of 
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healthcare reform, as suggested by the Institute of Medicine (2001, 2003), to provide 
patient centered care, to work in interdisciplinary teams, and employ evidence based 
practice. 
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Chapter Two: Review of the Evidence/Literature 
Due to the high cardiovascular risk, where “the risk of premature coronary heart 
disease (CHD) is elevated about 20-fold in untreated FH patients,” and the fact that FH is 
a treatable disorder affecting many undiagnosed young patients, an opportunity exists for 
improvement (Goldberg et al., 2011a, p. S135).  To identify if a lipid certified NP treating 
a population of probable FH patients would improve outcomes, a review of the literature 
was undertaken.  It should be noted that in the proposed project, the NP will be working 
collaboratively with an experienced lipidologist who has extensive training and expertise 
in this area. Team-based care has been supported in the literature, and will be included in 
the review.  
Topics of interest for research include the components of the PICO (Population, 
Intervention, Control group, Outcome) question:  In non-pregnant adults aged 20 years 
old or greater, with a diagnosis of probable heterozygous familial hypercholesterolemia, 
would treatment in a lipid clinic by a nurse practitioner compared to usual care (by non-
lipid-certified clinicians), lead to improvement in the LDL cholesterol at the end of a 3 
month period?  Specifically, the component topics of P-probable heterozygous familial 
hypercholesterolemia (FH) patients, the I-a group of patients treated by a lipid certified 
NP, the C-a comparative group of patients managed by usual care, and the O-improved 
lipids, were researched.  
The best available evidence was sought, based on the hierarchy of evidence, 
searching for systematic reviews of randomized controlled trials (RCT) first, followed by 
individual RCTs, cohort studies, case control studies, and finally, case reports.  In 
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addition, available guidelines for the treatment of blood cholesterol as well as FH and 
lifestyle management were sought to frame the EBP.  Further, scientific evidence 
supporting the diagnosis of heterozygous FH (HeFH) as well as treatments will be 
reviewed.  It should be noted that the literature search is not exhaustive and is meant to 
support the PICO-T.  
Methodology 
  A literature search was conducted using the term familial hypercholesterolemia, 
with Boolean modifiers limiting the search to English studies published between 1985-
2015, utilizing the databases of EBSCO HOST, MEDLINE, and CINAHL Complete.  
This returned 5,428 articles.  The search was narrowed to FH AND lipid clinic, yielding 
265 articles.  The search was further narrowed by adding AND heterozygous to the 
search, returning 75 articles which were all reviewed for applicability.  Additional 
searches were conducted using hypercholesterolemia AND lifestyle management 
returning 64 hits, while combining FH and National Lipid Association returned three.  
The 2013 AHA/ACC Guideline on Lifestyle Management as well as Make Early 
Diagnosis Prevent Early Death were also searched separately.  Clinical Trials.gov as well 
as EBM Reviews were searched for the ENHANCE and IMPROVE-IT trial information. 
Bibliographies were also examined to obtain pertinent articles.   In addition, personal 
communication with lipid experts aided in trial analyses and understanding of FH.  
Population 
 The population, non-pregnant adults aged 20 years old or greater, with a 
diagnosis of probable heterozygous familial hypercholesterolemia, was not random.  
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First, the treating practitioners work in an adult practice, limiting the population.  Statins 
are contraindicated in pregnancy, and pregnant FH patients are not an aim of this project.  
Second, the screening guidelines from the National Lipid Association (NLA), identify a 
population greater than or equal to 20 years old (Goldberg et al., 2011a).  Consistent with 
the objective of an evidence based project, age will be a limiting factor.   
Intervention: Treatment by a Nurse Practitioner 
Guidelines for blood cholesterol. 
  Individual approaches as well as population strategies have been recommended to 
improve cardiovascular health (Mozaffarian et al., 2015).  Advocacy and policy solutions 
as suggested by the AHA include ensuring “adherence to clinical guidelines and 
treatment protocols” (Mozaffarian et al., 2015, p. e51).  The 2013 ACC/AHA Guideline 
on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Risk in Adults was 
reviewed to determine applicability to the proposed EBP project.  Given that the 
guideline facilitates a strategy for risk assessment, it is not useful in a population, in 
isolation, with excessively high cholesterol numbers who are at high cardiovascular risk 
to begin with and where “risk stratification algorithms should not be used” (Goldberg et 
al., 2011a, p. 136).  Therefore, alternative guidelines were sought.  In addition, the 
evidence to support utilization of an LDL-C of > 190 was provided initially by the 
National Cholesterol Education Program Adult Treatment Panel III, in 2001, and 
reinforced by the NLA in 2011 and the International FH Foundation in 2014, as 
previously discussed (Goldberg et al., 2011a; Third Report of the National Cholesterol 
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Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults, 2002; Watts et al., 2014).  
Guidelines for screening and treatment of FH.   
The NLA offers clinical guidance from an Expert Panel on the screening, 
diagnosis and treatment of FH that will be used to facilitate this project.  The aim of the 
recommendations is to provide guidance for the primary care specialist as well as the 
lipidologist caring for FH patients.  The document provides a framework for treatment, 
and recommends adherence and persistence to recommended therapies, to reduce 
cardiovascular risk.  The recommendations are clear and concise for use as a tool in the 
aforementioned EBP and is highly applicable.  Authors are all lipid specialists and 
members of the National Lipid Association who have written extensively on the subject 
and are considered experts within the lipid community.  It is noted the development of the 
document was supported by a grant from many pharmaceutical companies, however, it 
was noted that the NLA had full scientific control over the content of the paper.  Most 
investigators have received honoraria from various drug companies, and disclosed this 
information.  
 It has been noted that the document was not meant to be a “comprehensive 
examination of the published literature” (Goldberg et al., 2011a, p.S134).  It is not clear if 
there were external reviewers, and there was no mention about future updates, however 
attention to future research needs was noted.  Specifically envisioned was “methods to 
enhance healthcare provider adherence to guidelines” (Goldberg et al., 2011a, p. S139), 
16 
 
 
which is consistent with recommendations from the 2015 Heart Disease and Stroke 
Update of 2015 from the AHA (Mozaffarian et al., 2015).   
Additionally, the NLA devoted an entire supplement to the Journal of Lipidology 
in 2011, to FH (Supplement 5).  Several articles, written by different authors, deal with 
the same issues: management, treatment, prevalence, and screening of FH patients.  The 
Executive Summary was a compilation of the work (Goldberg et al., 2011a).  This 
methodology is cumbersome to review and to use clinically, with noted redundant effort.  
Heterozygous FH studies. 
In searching for the highest level of evidence, it is noted that there is a dearth of 
double-blind, placebo-controlled, randomized trials of FH patients.  It is acknowledged 
that “in most clinical trials, individuals with LDL-C > 190 were not included due to their 
need for treatment” (Stone et al., 2013, p. 28).  However, as the next investigation 
reveals, studies have been done with patients on treatment.  
Smilde et al. (2001) investigated 325 FH patients, both men and women aged 30-
70 between 1997 and 1998.  Baseline characteristics were similar in both groups.  This 
was a prospective, randomized, double-blind trial, from the Netherlands.  The aim was to 
see whether a potent high dose statin regressed carotid intimal media thickness (CIMT), 
over 2 years, compared to a less potent statin.  Atorvastatin 80mg, the high dose statin, 
was compared with simvastatin 40mg, a less potent drug.  Patients were randomized by 
computer, with concealment.  Power, >80%, was noted; validity was high.  This was a 
very well designed study, approved by an ethics committee.   B-mode ultrasound, a 
reliable and valid tool, was used for measurement of CIMT.  
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Evaluation was on an intention to treat analysis, limiting bias.  After 2 years, the 
CIMT “in the atorvastatin group decreased (-0.031mm [95% CI -0.007 to -0.055]; 
p=0.0017), whereas in the simvastatin group it increased (0.036 [0.014-0.058]; 
p=0.0005” (Smilde et al., 2001, p. 577); results were statistically significant.  A limitation 
of this investigation was using CIMT as a surrogate for coronary artery disease (CAD).   
Notwithstanding, Smilde et al. (2001) convey: “in prospective studies, carotid IMT was 
able to predict coronary artery disease (CAD)” (p. 577).  Results demonstrated that 
aggressive LDL-C reduction regresses atherosclerosis in FH patients, while less 
aggressive treatment does not.  The study is highly applicable to the proposed PICO-T.  
Friedrich (2010), a doctorally prepared NP who is a clinical lipid specialist (CLS), 
offers a very thorough case study of a patient with HeFH that was identified and treated 
in a primary care practice setting.  Although low level evidence, the case presentation is 
highly applicable to the PICO-T question and provides a basic explanation of FH, as well 
as a historical perspective.  HeFH is further defined scientifically, and differentiated from 
homozygous FH (HoFH), exceedingly rare, occurring in 1 in a million people (Friedrich, 
2010).  Friedrich offers credence to the proposed methodology of a lipid certified NP 
treating FH patients, emphasizing the benefits of NP care including patient education, 
underscoring both pharmacotherapy and lifestyle changes necessary for management.  
The chronic disease of this cohort is recognized and acknowledged it as a public health 
issue as well.   
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Lifestyle management. 
The 2013 AHA/ACC Guideline on Lifestyle Management to Reduce 
Cardiovascular Risk will be used to guide lifestyle recommendations to the population in 
the proposed project, as lifestyle modifications are recommended by the NLA guidelines 
on FH (Goldberg et al., 2011a).  Patients who would benefit from LDL-C lowering are 
advised to follow a heart healthy prudent diet.   
Food plans aligned with this recommendation include the Dietary 
Recommendations to Stop Hypertension (DASH) dietary plan, the American Heart 
Association (AHA) Diet, or the U.S. Department of Agriculture (USDA) Food Pattern 
diet (Eckel et al., 2013).  All of these diets advise patients to “consume a dietary plan that 
emphasizes intake of vegetables, fruit, and whole grains; includes low-fat dairy products, 
poultry, fish, legumes, nontropical vegetable oils and nuts; and limits intake of sweets, 
sugar-sweetened beverages and red meat” (Eckel et al., 2013, p. 13, p.18).  For those with 
comorbid medical conditions such as diabetes, modifications are recommended.  The 
strength of this recommendation is Level A, developed from multiple populations, RCTs 
and meta-analyses with an NHLBI Grade A (Strong) treatment effect (Eckel et al., p. 5).  
Further, adults who are advised to lower their LDL-C are encouraged to “aim for a 
dietary pattern that achieves 5-6% of calories from saturated fat,” “reduce percent of 
calories from saturated fat,” and “reduce percent of calories from transfat” (Eckel et al., 
2013, p. 20).  
Additionally, the Lifestyle Guideline advises “adults to engage in aerobic physical 
activity to reduce LDL-C and non-HDL-C: 3 to 4 sessions a week, lasting on average 40 
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minutes per session and involving moderate-to-vigorous intensity physical activity” 
(Eckel et al., 2013, p. 29).  Again, the strength of this recommendation is ACC/AHA 
Level A, developed from multiple populations, RCTs and meta-analyses, with an NHLBI 
Grade B/Moderate treatment effect (Eckel et al., 2013, p. 29).   
The aim of the Lifestyle Guideline is to provide guidance for the prevention and 
treatment of cardiovascular disease through lifestyle modifications.  The 
recommendations are based on rigorous scientific systematic reviews and the highest 
level of evidence available.  In addition, recommendations were reviewed by expert 
panels.  Further, a limited number of individual expert reviewers assisted in the process.  
However, there was an extensive peer review process already in place.  The guideline 
was developed jointly by the ACC/AHA and NHLBI who have separate grading reports 
for strength of evidence.  This makes interpretation of some recommendations 
cumbersome and confusing.  It has been acknowledged that the authors did not review 
any evidence beyond 2011, and therefore will begin updating the guideline beginning in 
2014. 
The Lifestyle Guideline is highly applicable to the proposed project.  Tools such 
as hyperlinks to recommended diet plans are provided.  Recommendations are easily 
discernible in the text and clearly communicated.  Diet plans will be reviewed and 
available for print at patient encounters in the EBP change.  
Statins. 
One way to reduce cholesterol biosynthesis is to inhibit the pathway of 
production. “HMG-coA reductase is the rate- limiting enzyme in the cholesterol 
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biosynthetic pathway” (Tobert, 2003, p.518), and is a target of therapy, with a category of 
drugs called the HMG-coA reductase inhibitors.  All generic medications in this class end 
with the term “statin” and, thus, have been collectively and commonly referred to as the 
statins.  Lovastatin was the first statin approved for use in the U.S. by the Food and Drug 
Administration in 1987, followed by simvastatin and pravastatin in 1991 (Tobert, 2003).  
Since then, several have followed.  
The Cholesterol Treatment Trialists (CTT) collaborators joined in 1994 to 
perform prospective meta-analyses of data in a series of cycles.  The first cycle included 
over 90,000 individual patients in a total of 14 randomised statin trials.   Single trials 
often lacked the power to assess the effects of cholesterol lowering on morbidity and 
mortality particularly when individual subgroups were analyzed.  Specifically, the 
authors relate: “by weighing the results in individual trials and subgroups by the size of 
the achieved LDL cholesterol reductions, we were able to adjust for the potential 
confounding effects of such differences” (Baigent et al., 2005, p. 1275).  In the first cycle 
of study, participants were treated with statin therapy for a mean of five years, with a 
mean LDL cholesterol reduction of 1 mmol/L (38.6 mg/dL) at one year.  There was a 
21% reduction in any major vascular event (0.79, 0.77-0.81; p<0.0001), with benefits 
evident in the first year, but greater in subsequent years (Baigent et al., 2005).   Taking all 
years together, “the overall reduction of about one fifth per mmol/L LDL cholesterol 
reduction translated into 48 (95% CI 39-57) fewer participants having major vascular 
events per 1000 among those with pre-existing CHD at baseline, compared with 25 (19-
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31) per 1000 among participants with no such history” (Baigent et al., 2005, p. 1267).  
Most notably, 
The results of the present meta-analysis indicate that the proportional reductions 
in the incidence of major coronary events, coronary revascularizations, and 
strokes were approximately related to the absolute reductions inn LDL cholesterol 
achieved with the statin regimens studied, and that the proportional reductions in 
such major vascular events per mmol/L LDL cholesterol reduction were similar 
irrespective of the pretreatment cholesterol concentrations or other characteristics 
(eg. age, sex, or pre-existing disease) of the study participants (Baigent et al., 
2005, p. 1277).   
Therefore the results of the work by the CTT collaborators demonstrate that statin 
therapy can significantly reduce an individual’s vascular risk, over prolonged treatment, 
which also has positive similar implications for population health.  
In most of the contemporary lipid literature, it is commonly acknowledged that 
due to ethical reasons, randomized placebo-controlled trials are not performed in FH 
patients, as the patients are of high cardiovascular risk, and to withhold treatment from 
one group would not be morally sound.   Despite this acknowledgement, one RCT in 
heterozygous FH patients was located, from the late 1980s.  This was a double-blind, 
placebo-controlled multicenter trial that included five lipid clinics in the U.S. involving 
the first statin approved by the FDA.  The aim was to evaluate the effectiveness of 
lovastatin in 101 patients with HeFH, as determined by physical and laboratory 
characteristics.  There were 62 men and 39 women with a mean age of 44 years; both 
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groups were homogenous at baseline.  Patients were randomized to either placebo or 
varying doses of lovastatin, once or twice daily, over the 18 weeks of the investigation.  
Blinding as well as randomization was performed and discussed.  Standardization of 
laboratory analysis was ensured across all five clinics.   
Statistical analysis among groups was performed by a one-way analysis of 
variance.  T-tests or signed rank tests were used as needed.  Correlation was assessed by 
Spearman’s rank.  All 101 patients completed the study and there were no significant 
adverse effects.  Results were statistically significant:  
Significant reductions (p<0.01) in total plasma cholesterol and low-density 
lipoprotein cholesterol as compared with placebo were seen after 6 weeks of 
lovastatin therapy.  Mean reductions in total plasma cholesterol and low-density 
lipoprotein cholesterol ranged from 14% to 34% and 17% to 39%, respectively, 
for patients receiving lovastatin 5 to 40 mg twice daily for 6 weeks (Havel et al., 
1987, p. 611).  
The study demonstrated that lovastatin, in varying doses, was effective at 
reducing total cholesterol as well as LDL cholesterol, in a small group of patients with 
HeFH.  However, this was not a clinical outcomes study which is a limitation.  In this 
small investigation, power and intention to treat analysis were not considerations.  It 
should be noted that this study was performed at a time when statins were in the infancy 
stage, as well as the science of familial hypercholesterolemia.  For these reasons, it is 
likely that additional RCT of FH patients did not occur.  Study results, however are 
applicable to the proposed PICO question.   
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A large, long-term, prospective, cohort registry included patients on treatment.  
Investigators examined 3, 382 HeFH patients in 21 clinics in the United Kingdom from 
1980 to 2006.  The aim of the study was to assess all-cause, coronary and cancer 
mortality in FH patients before and after treatment with statins.  In keeping with the 
purpose of this review, only the cardiovascular segment will be discussed.    
Patients were identified as definite, or possible HeFH, based on the Simon 
Broome Register.  Using this methodology, the presence of tendon xanthomas as well as 
demographic information were assessed and registered.   Baseline demographics were 
similar, and available for review in table format.  Lipid assay was by the customary and 
widely used Friedewald formula.  Statistical analysis was performed by standard 
computer methodology for cohort studies.  
Investigators noted: “there was a significant excess in mortality from all causes 
before, but not after, 1 January 1992” (Neil et al., 2008, p.2627).  This finding correlates 
with the time frame when statins were being introduced.  The standardized mortality ratio 
(SMR) was “derived from the ratio of the number of deaths observed to those expected, 
which was expressed as a percentage” (Neil et al., 2008, p. 2626).  This key point assisted 
researchers in determining the number of expected deaths, which was used in data 
analysis.  From 1 January 1992 on, there were 153 coronary heart disease deaths, and 72 
expected, with an SMR of 213 (95% CI 181-250, p<0.0001), a statistically significant 
finding (Neil et al., 2008).  Although a cohort study is mid-level evidence, this study is 
clinically relevant to the proposed project.  
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Other pharmaceuticals.  
Statins are the mainstay of therapy for LDL-C reduction, as they have been 
proven to reduce morbidity and mortality, with strong scientific rigor (Stone et al., 2014).  
However, suboptimal reductions, drug intolerances, and continued cardiovascular events 
may necessitate a look at combination and alternative pharmacotherapy.  The evidence to 
support this was examined.    
Ezetimibe (trade name Zetia), has been studied in FH patients.  Ezetimibe is a 
cholesterol absorption inhibitor, and therefore has a different mechanism of action than a 
statin.  Two investigations utilizing ezetimibe will be reviewed.  The first, called 
ENHANCE, the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances 
Atherosclerosis Regression trial, was an international, double-blind, RCT over 24 months 
duration, from 2002-2006 and included 720 male and female HeFH patients.  (Indeed the 
study dates were 2002-2006, and the investigation period was 24 months, as written.)  
Participants were from 18 centers in eight countries, including the Netherlands, Canada, 
the United States, South Africa, Spain, Denmark, Norway and Sweden.   
The aim of the study was to compare the effectiveness of high dose simvastatin, 
80mg, and placebo, to high dose simvastatin, 80mg plus ezetimibe 10mg and placebo on 
carotid intima media thickness (CIMT), a marker of atherosclerosis.  The primary 
endpoint was the change in the mean of CIMT by B-mode ultrasound measurements.  All 
participating centers required institutional review board (IRB) approval, and obtained 
informed consent from participants.  There were strict inclusion and exclusion criteria, 
including either a genetically determined diagnosis of HeFH, or a strict clinical one, 
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necessitating meeting specified characteristics and parameters.  Notably, 80 % of patients 
in both arms were already on some statin therapy at entrance.  Additionally, compliance 
with the recommended therapy was accounted for by tablet count.  
Randomization of patients occurred through a computer generated code.  In 
addition, providers were rigorously trained and certified ultrasonographers were blinded 
to the patients.  B-mode ultrasound, which is reliable, validated and widely available, was 
utilized to obtain CIMT measurements.  
Evaluation was on intention to treat analysis, with a power of greater than 90%, to 
detect a difference of 0.05 mm in carotid measurements, limiting bias and improving the 
reliability of the results.  However, authors disclosed that the study was not powered to 
assess clinical outcomes.  The investigation was supported by the drug sponsors, Merck 
and Schering-Plough, however it was noted that all study components were of scientific 
merit, on the authors behalf. 
Outcomes were obtained through covariate analysis models, using SAS software. 
“The primary outcome, the mean ( + SE) change in the carotid-artery intima-media 
thickness, was 0.0058 + 0.0037 mm in the simvastatin-only group and 0.0111 + 0.0038 
mm in the simvastatin-plus-zetia (combined therapy) group, P=0.029” (Kastelein, 2008, 
p.1431).   Therefore, the combination therapy did not decrease CIMT more than statin 
therapy with simvastatin alone.  However, the authors also noted:  
After 24 months, mean levels of LDL cholesterol decreased from  
317.8 ± 66.1 mg per deciliter (8.22 ± 1.71 mmol per liter) to 192.7 ± 60.3 mg per 
deciliter (4.98 ± 1.56 mmol per liter) in the simvastatin-only group and from 
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319.0 ± 65.0 mg per deciliter (8.25 ± 1.68 mmol per liter) to 141. 3± 52.6 mg per 
deciliter (3.65 ± 1.36 mmol per liter) in the combined-therapy group, a between-
group difference of 16.5% (P<0.01; p.1437).   
In addition, there were marked reductions in the levels of triglycerides, C-reactive 
protein, and apolipoprotein-B levels in the combined therapy group versus the 
simvastatin group that was statistically significant, but not a primary or secondary 
outcome (Kastelein et al., 2008).   
Therefore, there was no significant decrease in CIMT despite higher degrees of 
reduction in LDL-C, triglycerides, CRP, and apolipoprotein-B compared to simvastatin 
only therapy.  One wonders whether the study was poorly designed--in that there was no 
statistical difference in CIMT because patients were already on adequate therapy with 
statins, or perhaps because the study wasn’t long enough, or some other unexplained 
reason.  Notably though, this was a study about a drug effect on CIMT, not clinical 
outcomes, but held promise to those believers in “the lower, the better, hypotheses,” 
referencing reductions in LDL-C, triglycerides, apolipoprotein-B, and CRP, which 
predicated future outcome studies with ezetimibe (personal communication, T. Dayspring 
MD, FACP, FNLA, NCMP, Director of Cardiovascular Education, Foundation for Health 
Improvement and Technology, February 16, 2015).  
 More recently, a randomized, placebo controlled trial titled IMProved Reduction 
of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), sought to investigate 
the efficacy of simvastatin versus simvastatin and ezetimibe on clinical outcomes, in high 
risk patients.  Final results were recently published in the New England Journal of 
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Medicine (Cannon et al., 2015).  There were 18,144 high risk patients, with a recent acute 
coronary syndrome, randomized to receive either simvastatin 40 mg or simvastatin 40 mg 
and ezetimibe 10mg.  It is known that ezetimibe when added to statin therapy provides an 
additional 20% LDL-C reduction (Canon, 2015).  What was not known is whether the 
addition of ezetimibe would change clinical outcomes, i.e. cardiac events.  Primary 
endpoints of the study were cardiovascular death, myocardial infarction, stroke, re-
hospitalization for unstable angina, or coronary revascularization greater than or equal to 
30 days post randomization.  
 There were strict inclusion and exclusion criteria, with similar baseline 
characteristics of both groups.  There was sufficient power, >90%, to determine clinical 
outcomes.  Data was evaluated on an intention to treat analysis, limiting bias.  The study 
was drug company sponsored, however all academic rigor was given to the study authors.   
 Results demonstrated a statistically significant decrease in cardiac endpoints, at 
the end of 2.5 years of follow up in the simvastatin/ezetimibe group vs the simvastatin 
group (32.7% vs 34.7%, HR=0.94, 95% CI 0.89-0.99; p=0.016; Cannon, 2015).  This 
supports the hypothesis that the lower the LDL-C, the better the atherosclerotic risk 
reduction.   In addition, these results demonstrate a statistically significant reduction in 
clinical outcomes when ezetimibe was added to statin therapy, in high risk patients with 
established CAD.  It is unclear if these results can be extrapolated to low risk patients.  
However, this investigation provides support for adding ezetimibe to high risk patients, to 
reduce LDL-C, and is applicable to the proposed EBP.  
28 
 
 
   Additionally, there are two novel pharmaceutical agents that have been developed 
and approved by the FDA for treatment of FH patients:  lomitapide and mipomersen.  
However, at this time, their use is restricted to treating homozygous FH (HoFH) patients.  
Studies are currently ongoing to expand the indications, and in the future, may be 
appropriate for treating HeFH.  Therefore, at this time, these agents are not available for 
use in the population of patients in this project.  
Team based care. 
A systematic review of practice guideline dissemination and implementation for 
healthcare teams was analyzed, using the Joanna Briggs Institute’s (JBI) approach, within 
a high level of the hierarchy of evidence.  The aim was to evaluate the effectiveness of 
clinical practice guidelines for collaborative care and patient outcomes.  Eighty-eight 
articles were included in the final analysis, starting from an initial pool of over 12,000, 
published between 1995 and 2007.  Included were RCTs, descriptive/case series, or 
cohort/case control studies.  Papers were reviewed by a minimum of two reviewers; a 
third was used if needed as a tiebreaker.  This approach provided a high level of validity.  
In addition, a standardized critical appraisal instrument from the JBI was utilized, 
increasing the reliability of the results.   
Overall, ten guideline dissemination and implementation strategies were gleaned 
from the 88 articles.  Examples included laminating of guideline cards, mass media 
presentation, and distribution of educational material and poster displays.  The 
descriptive analysis reported favorable results, with 72.7% of the studies reporting teams 
to have enhanced “knowledge, practice, and /or outcomes” (Medves et al., 2010, p.79).  
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Diagrams and tables complemented the presentation and discussion of the findings.  
Limitations were the varied and inconsistent methods of guideline dissemination amongst 
the studies.  
In conclusion, investigators support the use of evidence based guidelines in team 
based care, to enhance patient and provider outcomes.  This is highly consistent with the 
proposed evidence based project, using guidelines to identify and treat a specific patient 
population, under the care of an advanced practitioner collaborating with a lipidologist.  
The ACC supports a vision to “dramatically reduce the incidence, severity and 
complications of cardiovascular disease as we promote prevention, reduce disparities in 
health care, and improve personal and population-based cardiovascular health” (ACC, 
2015a).  The College is strategic in formulating guidelines to lead and shape 
cardiovascular health across our nation.  In recognition of that vision is the College’s 
support of team-based care.  On the ACC President’s Page (Brindis, Rodgers & 
Handberg, 2011), an emphasis is placed on the value of the contributions of “non-
physicians” [sic], including both physician assistants (PAs), and nurse practitioners 
(NPs), in providing high quality patient centered care.  Additionally, the College recently 
published its 2015 Health Policy Statement on Cardiovascular Team-Base Care and the 
Role of Advanced Practice Providers (APP), providing a formal position on the issue 
(Brush et al., 2015).   In fact, an APP functioning in a lipid clinic as a provider in a 
disease-state management, was an exemplar case of team based care in the health policy 
(Brush et al., 2015).  
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Although low level evidence, the College conducted a survey in 2010 of over 
2,400 cardiovascular practices, representing 14,000 cardiologists across the U.S.  The aim 
was to gain a better understanding of the benefits of team-based care.  Results disclosed 
that team care enhanced patient education, as reported by 69% of respondents, while 63% 
related improved efficiency and 50% conveyed improved patient adherence (ACC, 
2015b).  Additionally, 33% percent suggested enhanced outcomes utilizing PAs and NPs 
to provide collaborative care in lipid clinics, device clinics, and anticoagulation clinics 
(ACC, 2015b).  Notably, the landscape of cardiovascular care is changing, with 
opportunities on the horizon for the advanced practitioner.  Reflective of the current 
status of clinical cardiovascular practice, the survey results do demonstrate clinical 
significance to the proposed PICO-T question. 
Allen et al. (2002), in a RCT, tested the effectiveness of an NP in managing lipid 
abnormalities in patients with known coronary heart disease.  Included in the study were 
228 hospitalized patients from a large tertiary medical center, randomized by computer to 
either care by an NP, or usual care, by the primary care provider or cardiologist, after an 
acute coronary syndrome.  Blinding however, was not discussed.  In addition, it did not 
appear that the NP held a lipid certification. 
 Baseline characteristics of both groups were comparable.  Interventions included 
the standard of care incorporating pharmacotherapy, diet instruction and a personalized 
exercise prescription.  There was additional emphasis placed on lifestyle management in 
the NP arm, with a focused analysis on improvements in exercise and dietary habits.  
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Follow-up visits occurred up to a year after discharge, in person or by phone, in the 
intervention group.  Lipid levels were reexamined at one year.    
Data were assessed by an intention to treat analysis, decreasing potential bias.  
Results demonstrated a statistically significant achievement of an LDL-C goal of <100 
more often in the NP group than in the usual care group (65% vs 35%, p=.0001; Allen et 
al., 2002, p.683).  Limitations included the possibility of a type II error, with a narrow 
intention to treat analysis, with a moderate sample size.  
The investigation by Allen et al. examined secondary prevention, with those 
known to have coronary heart disease (CHD), differing from the population of the 
proposed EBP.  However, both are considered to be high cardiovascular risk groups.  
There is a high degree of correlation between the intervention and outcome of this RCT 
and the proposed project, supporting the suggested approach for treatment of lipids by an 
NP.  
Another investigation, a cohort study by Shafer and Wexler (1995), compared 
treatment of lipids in a multidisciplinary lipid clinic with that of usual care.  The 
convenience sample with age matched cohorts included 120 patients, 60 from the 
Cincinnati, Ohio, VA Lipid Clinic and 60 from a general internal medicine (GIM) clinic, 
in a retrospective chart review.  The intervention group was treated by a multidisciplinary 
team including an NP, dietician, pharmacist, nurse and psychologist.   
Lipids were examined after 12 months in the Lipid Clinic and after 18 months in 
the GIM clinic.  Results demonstrated that patients in the Lipid Clinic were four times as 
likely to reach lipid goals as those in the GIM clinic with a relative risk ratio of 4.1 
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(95% C.I. 1.4-12.7; p<.001; Shafer & Wexler, 1995, p.2330).  The results are statistically 
and clinically significant to the proposed project.  Limitations were the design and non-
random, convenience sample, which increases potential study bias.  The prospective 
design predisposes the providers to bias as they are aware the patients are in a study.  
Adherence and persistence. 
Assessing adherence and persistence to treatment plans, particularly to 
medications such as statins, would be an important metric in RCTs examining mortality 
and morbidity in high risk patients.  Simpson and Mendys (2010) performed a systematic 
review of the effects of adherence and persistence on clinical outcomes in patients treated 
with statins.  They analyzed 19 total articles quantifying adherence (n= 15) and 
persistence (n=4) in treatment with statins to clinical outcomes, through a PubMed search 
of English articles published between 1999 and 2009.   Investigations were performed 
either in Canada or the U.S. and excluded reviews and nonclinical studies.  Three studies 
were primary prevention and eight were secondary prevention trials.  There were 
inconsistencies in defining adherence and persistence among the studies examined which 
made data analysis difficult.  In fact, no definition of persistence was disclosed.  
Adherence was defined as the portion of days covered (PDC), or the number of days 
medication is supplied, divided by the observation time interval.  A commonly accepted 
threshold was defined as 80% or greater, over the period observed.  
The reliability and validity of the investigation could not be verified; there was no 
valid tool used and patients self-reported if they were taking the medications.  
Investigators reported descriptive results in an easy to read table.  In primary prevention 
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studies, benefits were derived at one year of therapy or longer.  High levels of adherence 
were associated with a decrease in all-cause mortality, and nonfatal cardiovascular events 
with adherence >80% (Simpson & Mendys, 2010).  A weakness of the analysis, is the 
number of studies examined and the lack of consistent definitions of critical concepts.  
This weakens the overall conclusions.   Adherence to recommended treatments to reduce 
cholesterol levels is applicable to the PICO-T presented.   
Darves (2003) described a retrospective study of 70 patient charts, assessing 
improvement in LDL cholesterol in an NP managed lipid clinic.  An aim of the study was 
to indirectly assess medication adherence, as measured by improved lipids.  In this small 
investigation, the average patient was 70 years old, and 67% were male.  Patients had a 
33% reduction in average LDL cholesterol and 75% of the patients met established goals 
(Darves, 2003).  Limited information was available from the presented study abstract, 
however it was noted that limitations included the small sample size, and lack of baseline 
lipid levels in some patients.  Despite the study’s low level of evidence, it was included in 
the review, as it is highly applicable to the identified PICO-T and supports the EBP.  
Control Group: Usual Care 
Birtcher et al. (2010) performed a retrospective, cohort observational study, to 
determine if lipid management of patients with established CAD cared for in a 
multidisciplinary clinic (SPLC), would improve adherence to the established lipid 
guidelines, compared to usual care, as measured by the lipid profile, at the end of three 
years.  A total of 1,433 people, 415 in the specialty clinic, and 1018 in comparative 
group, were recruited from a computer database and included in this investigation from a 
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large subspecialty practice in Texas.  Patients in the multispecialty clinic were cared for 
by both cardiologists and pharmacists, and patients in the usual care group were provided 
care by cardiologists alone.  Patients in the multispecialty clinic achieved “LDL-C goals 
more often than usual care cardiology patients (goal<100 mg/dL:  81.9%, vs. 72%, P 
<.001; optional goal, 70 mg/dL: 41.9% vs. 28.6 %, P< 001; Birtcher et al., 2010, p. 46).  
This was statistically significant.  
By design, this study offers mid-level evidence in the hierarchy of scientific vigor.  
The applicability to the proposed project is in the analysis of the results of the 
performance of usual care, which will be similar, but not exactly to, the comparative 
group.   Usual care in the proposed project will be by either the primary care provider or 
cardiologist.   The results of the examined study do demonstrate that an alternative model 
of care can be more successful than usual care in treating patients with established CAD, 
who are high risk, when compared to usual care.  Therefore, this investigation is highly 
applicable to the proposed project.  
Another study examined lipid lowering therapy, as well as other clinical 
characteristics, in a prospective, cross-sectional analysis of a longitudinal cohort study, 
consisting of a total population of 1,852 patients from 19 lipid clinics in Spain.  
International FH guidelines provided the framework for this particular investigation 
which has been titled SAFEHEART, the SpAnish Familial HypErcHolEsterolemiA 
CohoRt STudy.  Genetic testing with DNA assays was used to confirm the diagnosis of 
FH in this population. 
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Results disclosed that “only 3.4% of patients reached and [sic] LDL-c [sic] under 
100mg/dL” (Mata et al., 2011, p. 1), however, ‘half of this population were receiving 
treatment to reduce LDL-C > 50%” (Mata et al., 2011, p. 6).  The investigators did 
discuss the International FH guideline LDL-C goals: “the optimal LDL-c [sic] goal 
should be 100 mg/dL or to achieve at least a 50% reduction in LDL-c [sic] levels” (Mata 
et al., 2011, p. 6).  Based on either goal, this investigation demonstrated that there is still 
significant room for improvement in the management of lipids in FH patients.  This study 
is highly applicable to the proposed PICO project, and offers additional mid-level 
evidence from a well-designed cohort study.  
Outcome: Improved Lipids 
Goals of treatment of lipids for FH have been established.  According to the NLA 
FH Expert Panel: “For adult FH patients, initial treatment is the use of moderate to high 
doses of high potency statins titrated to achieve an LDL cholesterol reduction  > 50% 
from baseline” (Goldberg et al., 2011a, p.138).  However, some FH patients with other 
comorbidities, and those with established coronary heart disease, may require greater 
LDL cholesterol reductions, beyond 50% (Goldberg et al., 2011a).  Modifications, 
including alternative therapies with other medications are recommended for those 
intolerant of stains. These pharmaceuticals may include ezetimibe, niacin, or a bile acid 
sequestrant or combination therapy (Goldberg et al., 2011a).   Additional therapies such 
as LDL apheresis are available for specific cases, but will not be a part of this particular 
project.   
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Limitations 
The limitations of the review are based on the studies examined, as the search was 
not an exhaustive one.  It included studies available in the databases searched, under the 
particular key words.  
Conclusions 
There is strong evidence to support the need for better lipid management in 
patients with high cholesterol levels.  The population in this project is well established, 
by the framework of the aforementioned guidelines.  The NLA FH recommendations are 
moderately supported by the available evidence, as there are few scientific studies of high 
level evidence, with randomized, controlled and blinded studies in a population that is 
known to be high risk.  The display of the recommendations from the NLA would be 
more clinically useful if combined into one document, instead of many papers in a 
supplement.   
The diagnosis of HeFH is well supported and treatment goals are well delineated, 
with strong scientific support for the use of statins, and ezetimibe.  However, there are no 
clinical outcome studies on other pharmaceuticals such as fibrates, niacin and bile acid 
sequestrants, although supported for use by the NLA recommendations, if clinically 
necessary.  Therefore, there is scientific merit for treatment with statins, ezetimibe, and 
lifestyle management.  Emphasis will be placed on these strategies for patients in the 
project.  Other modalities will not be excluded however, if there are drug intolerances, or 
additional therapies are required to meet goals.   
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There is clinical support from field experts in cardiology, on behalf of team based 
care, by the ACC.  In addition, there was an excellent systematic review using the JBI 
approach supporting healthcare teams, the use of guidelines and improved outcomes.  
There was moderately high evidence for the support of an NP treating lipids in a specialty 
clinic, compared to usual care.  Furthermore, good studies on adherence and persistence 
to recommended treatments are lacking, and perhaps the available study in this review 
sought to examine two separate constructs in one study making analysis difficult.  
Further, the lack of clear definitions of adherence and persistence makes the prospect of 
scientific vigor less promising.  
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Chapter Three: Organizational Framework/Conceptual Model for Evidence Based 
Practice Change 
According to the World Health Organization (2002), chronic conditions are the 
health care challenges of the 21st century.  The World Health Organization offers a 
compendium of information and discussion about chronic conditions, as a call for action 
by policy leaders and decision makers who have the capacity to alter the course of 
chronic disease management in a positive fashion (2002).  It is clear that without a better 
emphasis on preventive medicine, the cost of caring for those with chronic conditions, 
such as heart disease, cancer, diabetes and depression for instance, will be 
insurmountable.  Elements for attention include: (a) a focus on prevention, (b) integrated 
health care, incorporating primary care, community resources, and inpatient as well as 
outpatient care, with facilitated shared information, (c) the utilization of health care 
professionals to the fullest extent of their education, and (d) an emphasis on patient 
centered care (WHO, 2002).  
Defined, chronic conditions are “health problems that require ongoing 
management over a period of years or decades [sic],” (World Health Organization, 2002, 
p.11) and are inclusive of heart disease.  A call for innovation to manage chronic 
conditions is made.  Further, a correlation across the conditions is made: 
Innovative care is not based on the etiology of a particular problem, but is based 
on the demands that the health problem places on the health care system. In the 
case of chronic conditions, the demands are similar regardless of the cause of the 
condition.  Moreover, effective management strategies are remarkably 
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comparable for many chronic problems, and chronic conditions management, 
inclusive of all chronic health problems, is developing an identity of its own in 
health care (World Health Organization, 2002, p.44). 
A framework for organizing health care for chronic conditions is therefore introduced.  
Specifically, a model called the Chronic Care Model (CCM), will be used for this 
evidence based project. 
Conceptual Definitions 
The Chronic Care Model (CCM) was developed by Dr. H. Wagner, and 
colleagues at the Seattle based MacColl Center for Health Care Innovation at the  
Group Health Research Institute, in conjunction with the Robert Wood Johnson 
Foundation (RWJF), in the 1990s.  It was designed as a utilitarian model with 
applicability to groups of patients in diverse populations with chronic illness.  The model 
is “a synthesis of evidence-based system changes intended as a guide to quality 
improvement and disease management activities” (Wagner et al., 2001, p. 69).  It has 
since been further modified with an international applicability to populations as a whole.   
The original CCM has interacting components whereby “the system changes 
support the development of informed activated patients and prepared proactive healthcare 
teams whose interactions become more productive and satisfying around chronic illness” 
(Epping-Jordan, Pruitt, Bengoa, & Wagner, 2004, p.300).  (See Appendix A for a 
diagram of the CCM; Wagner, 1998b.)  When these integrated components function 
optimally, good chronic care is achieved, and customers, including the clinician as well 
as the patient, are satisfied, with improved outcomes. 
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Overall, there are six elements that comprise the CCM.  The Health System is a 
part of the bigger Community, whereby community resources as well as the health care 
organization itself are two interacting components of the Model.  The Health System 
organization includes four interacting elements: self-management, delivery system 
design, decision support, and clinical information systems (Epping-Jordan et al., 2004; 
Pearson et al., 2005).  Self-management support incudes care to the patient and/or family, 
and includes empowering the client by providing proper tools and education for success.  
Further, it epitomizes patient centered care.  Delivery system design entails a description 
of and setting of the encounter, as well as the specific provider.  This is a key component 
of the systems change [emphasis added].  Team care is inferred, with innovative delivery 
system redesign.   
Decision support refers to the evidence based guidelines that frame the care.  In 
addition, it encompasses the integration of expert consultation that may be indicated, as 
well as educational tools to assist the clinician.  Clinical information systems enhance the 
sharing of information between providers, and can create reminders for follow-up visits, 
lab work, and medication refills, for instance, to facilitate adherence.  Furthermore, 
disease registries can offer a database to manage process improvement and performance 
evaluations.   Critically, it is noted that “the improvement in the care of patients with 
chronic illness will only occur if system leaders, whether private or governmental, make 
it a priority and provide the leadership, incentives, and resources necessary to make 
improvements happen” (Epping-Jordan et al., 2004, p. 300).   
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Utility of Model 
Coleman, Austin, Brach, and Wagner (2009) provide a review of evidence 
supporting the use of the model in guiding quality initiatives in ambulatory care over ten 
years.  The Model has been used in over 1,500 medical practices, including primary care 
offices, patient-centered-care home models, and in the Heath Disparaties Collaboratives 
(HDCs) as well as the Improving Chronic Illness Care (ICIC) Collaborative (Coleman et 
al., 2009).  It has also been the basis for many state, national, and international system 
changes.  Clinically, several works have described it as a successful model for patients 
with congestive heart failure, diabetes, asthma, depression, and lipid management 
(Hallady et al., 2014; Khatana, Liang, & Wu, 2014; Pearson et al., 2005; Stock et al., 
2014).  Furthermore, use of the CCM has been described by U (2012) in conveying care 
provided by family nurse practitioners in family medicine.  This underscores the 
applicability for use in the proposed EBP.  
Relationship of Model to Project 
The following will describe a correlation of the model elements to interventions  
in the proposed project.  
1.  Self- management interventions- Patients will be able to verbalize an understanding of 
their treatment goals, to facilitate adherence.  Patient centered educational material, as 
produced by nationally respected organizations such as the National Lipid Association 
(NLA), the Preventive Cardiovascular Nurses Association (PCNA), the U.S. Department 
of Health and Human Services (U.S. DHHS) and the U.S. Department of Agriculture, for 
instance, will be integrated through the EHR and available for print at the closure of each 
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patient encounter, as ordered by the provider.  Material will encompass lifestyle changes, 
exercise, diet and pharmaceutical information sheets, to strengthen self-management 
skills. 
2. Delivery system design- Delivery system for the project population will be specifically 
with a nurse practitioner (NP) who is a clinical lipid specialist (CLS).  Care will be 
provided through a team approach, with the NP working collaboratively with a board 
certified lipidologist.  Encounter visits will be documented through the electronic heath 
record (EHR) to facilitate communication with the primary care provider as well as other 
specialists.  Follow up phone calls will be made to promote adherence to the treatment 
plan.  
3.  Decision support- Guidelines offered by the NLA will be used to guide lipid treatment 
goals and pharmaceutical recommendations, while guidelines from the ACC/AHA will 
provide recommendations for diet and exercise.  Expert clinician assistance will be 
available through the collaborative work with a lipidologist.  
4.  Clinical information systems- An electronic database will be used to identify those 
patients with probable familial hypercholesterolemia, to facilitate the patient population.   
All patient encounters with the NP will be documented within an EHR.  Any required 
testing will be ordered through the EHR.  Follow up visits will be coordinated through 
use of the EHR as well.  In addition, ongoing, daily, electronic communication between 
the office staff and the NP will provide an avenue for patients’ calls and questions to be 
answered in a timely manner.  
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5. Health System Organization and Care- The development of a lipid clinic, in which the 
proposed evidence based project is a part, has been supported by administration. The 
strategic plan in fact, was coordinated by the management team, with network wide 
communication marketing the notion, demonstrating commitment on behalf of the 
cardiac service.  
6. Community Resources and Policies- Patients will be offered referrals for Medical 
Nutrition Therapy (MNT) to review recommended diets, on a one-on-one approach with 
a registered dietician.  Recommendations for community agencies offering exercise 
facilities will be provided, including the Network’s gyms, to facilitate compliance with 
local amenities.  Participation in community resources will be encouraged.  
7. Improved functional and clinical outcomes- Outcomes will be assessed by percent 
change in the TC and LDL-C at 12 weeks.  
These interventions are consistent with those proposed by Wagner et al., (2001) and the 
Chronic Care Model.   
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Chapter Four: Project Design 
 The project will be conducted using a comparative design using a prospective 
intervention group and a retrospective comparison group.  There will be a pre-
intervention allocation to two groups, an intervention and a comparison group, based on 
an electronically identified LDL-C >190.    Based on the setting of the comparison group, 
a true randomized intervention is not possible.  However, the design will likely 
strengthen the project, minimizing bias, with analysis of results performed in a real-world 
setting.  This is a feasible and alternative inquiry to randomization, in a practice based 
setting, as demonstrated by review of the literature (Bonell et al., 2011).   
Protection of Human Subjects Research 
 Appropriate educational standards have been met to ensure the safety and 
protection of human subjects. Collaborative IRB Training Initiative (CITI) research 
modules were completed and achievement certificates presented, as required for human 
subject research.  In addition, a web-based training course was completed as offered by 
the National Institutes of Health (NIH) Office of Extramural Research titled Protecting 
Human Research Participants.    
 Organizational consent on behalf of St. Luke’s University Health Network was 
obtained by signature on the IRB application, from the Vice President of Operations of 
Cardiovascular Medicine, Kevin McGovern, as well as the Chairman of Cardiovascular 
Medicine, Raymond Durkin, M.D., and the collaborating physician, lipidologist Gerald 
Pytlewski, D.O.  IRB approval as a Type I Exempt review was met, from both St. Luke’s 
University Health Network, and Misericordia University (see Appendix B and D).  
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Additionally, St. Luke’s provided a letter of support (See Appendix C), as the population 
of patients originates from the St. Luke’s Network.  Additionally, the St. Luke’s standard 
Informed Consent Form will be used, as required by the collaborating institution (See 
Appendix E).  
Data Collection Tools  
Lipids will be assessed utilizing a standard 12 hour fasting lipid profile, which 
estimates the LDL using the Friedewald formula.  In this method LDL cholesterol is 
estimated by figuring “the total cholesterol minus high-density lipoprotein (HDL) 
cholesterol minus very-low-density lipoprotein (VLDL) cholesterol (estimated as 
triglyceride ÷ 5)” (Warnick, Knopp, Fitzpatrick & Branson, 1990, p. 15).   
Because ultracentrifugation is unavailable in most routine laboratories and the 
procedure is expensive, time consuming, and technically demanding, the nearly 
universal approach in clinical laboratories (and that used commonly even in 
specialized lipid laboratories) has been to estimate LDL cholesterol from the 
formulas of Friedewald et al. (Warnick et al., 1990, p. 15).  
Plan for Evaluation 
 Data analysis will be in percent change of LDL-C, at four weeks for the treatment 
group and 12 weeks for the comparison group.  The 2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol indicates lipids should be rechecked in 4-12 weeks after 
initiating statin therapy, to assess for patient safety and adherence (Stone et al., 2013).  
Additionally, a treatment goal for this population has been established: “for adult FH 
patients (>20 years of age), drug treatment to achieve an LDL cholesterol reduction  
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> 50% should be initiated” (Goldberg et al., 2011a, p.136).  Therefore, outcomes will 
address provider adherence to the guidelines, as well as measurement of LDL cholesterol 
reduction. Data will be analyzed, with the assistance of Jill Stotltzfus, PhD., Director of 
Clinical Research of St. Luke’s University Health Network.  The time frame for the 
project was narrowed, based on the timing of IRB approvals, and patient recruitment.  
Resources Needed 
 An organizational change such as the one planned, requires the support of 
administration, the Chief of Cardiology, cardiologists, and referring providers, as well as 
the support of information technology and medical assistants.  Leadership champions 
such as Kevin McGovern, FACHE, Vice President of Operations at St Luke’s University 
Health Network, and Raymond Durkin, MD, Network Chairman of the Department of 
Cardiovascular Medicine, have been instrumental in the development of a Lipid Clinic, of 
which this project is a component.  Successful transformational leadership understands 
that “people need to be empowered to take charge of the design of their own learning and 
to alter their roles and behaviors in response to what they discover” (Porter-O’Grady & 
Malloch, 2015, p. 480).   As visionaries, they are able to anticipate and plan for the 
changes in healthcare, based on recent statutes.  
 The 2009 Health Information for Economic and Clinical Health Act of 2009 
(HITECH) Act was legislation passed by the Federal government that has brought about 
widespread use of health technology.  This regulation financially incentivizes institutions 
for using electronic health records (EHR) as components of “meaningful use,” whereby 
patient safety, quality and care coordination are enhanced and use of Clinical Decision 
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Support Systems (CDDS) are integrated into the EHR.  The aim is to improve outcomes 
and quality, based on evidence based care (Murphy, 2014), as well as encourage patient 
engagement (Beaty & Quirk, 2015).  Given this regulation, providers and institutions will 
be held accountable if process outcomes are substandard.  In this fashion, population 
health and preventive medicine can be improved.  The Clinical Quality Solutions (CQS) 
program by the Team Praxis available through St. Luke’s Allscripts EHR provides a tool 
to identify populations of people with probable FH.  
 Regulatory efforts emphasize commitment to the cause. The Office of the 
National Coordinator for Health Information Technology (ONC) performs ongoing 
research and data analysis related to the use of health information technology (HealthIT).  
Case studies, data briefs and exemplar analyses are disseminated widely on a 
HealthITDashboard by the ONC (HealthIT.gov. 2015).  Despite governmental 
regulations, it has yet to be firmly established that the promise of enhanced health IT will 
reduce costs, and improve quality (Sherer, 2014).  Sherer (2014), a professor of 
Information Systems at Lehigh University, whose research interests include health IT, 
advocates for action designed research (ADR), using existing theory as a framework. 
Sherer suggests that traditional methods of research, in retrospective analyses, will miss 
opportunities for influencing current practice changes.  She underscores the importance 
this work be accomplished in a multidisciplinary fashion, with economic experts, 
information technologists, providers, payers, and healthcare managers.  Sherer’s 
reflections are notable in this vastly changing environment of the Digital Age in 
healthcare.  One needs to consider endpoints and economics.  
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 Key stakeholders in the project are the cardiologists, referring providers and 
patients themselves.  Patients have developed relationships with their usual providers and 
intrusion into that relationship can cause apprehension for some.  Kennedy & Nordrum 
(2015), discuss the successes and barriers of population health management in a family 
practice setting.  While it has been recognized that NPs provide cost-effective, quality 
care, patients remain loyal to their doctors.  A call for managers and administrators to 
employ practice redesign to ensure NPs function at the highest level of their education, 
have been made by several authors (American Association of Nurse Practitioners, 2015; 
Bauer, 2010; Kennedy & Nordrum, 2015).  The design of the proposed EBP is consistent 
with these goals.    
 Additional resources such as personnel support by the medical assistants and 
information technology experts are invaluable.  The support of individuals familiar with 
the outpatient electronic health record will ease the burden of use by a new user, and will 
assist with printing of documents such as medication profiles, educational materials and 
lab requisitions.  The Director of Allscripts Data Entry, Bonnie Smith, was instrumental 
in integrating all of the educational materials and inputting them into the electronic health 
record, centrally located, in a Lipid Care Guide.  The need for integrating this 
information was supported by the Vice President of Operations of Cardiovascular 
Medicine, who facilitated meetings to accomplish this goal.  
Budget Justification 
There is no specific budget justification necessary for the implementation of this 
project.  However, use of the electronic health record will generate the medication profile 
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and side effect list, as well as educational materials such as the diet instruction, and 
recommended lifestyle modifications.  This will require paper and ink to print.  These 
materials are expenses incorporated into general office visits of the practice, and will not 
contribute to excessive paper and ink, requiring a budget justification.  Medical assistants 
function to help all providers, and electronic record support from Allscripts EHR are all 
part of routine office care.  
Conclusion 
 The proposed EBP compares measurements of patients’ lipids with probable FH, 
treated by an NP in collaboration with a lipidologist in a lipid clinic, to usual care. It is 
grounded on a chronic care model, with an emphasis on the use of integrated, evidence-
based care using informatics.  
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Chapter Five:  Implementation Procedures and Processes 
 An EBP vision was developed based on the clinical and personal experience of 
the investigator, which includes a strong interest in risk factors associated with the 
development of cardiovascular disease.   Why young people in particular die from heart 
disease, stimulated further inquiry as well as certification in lipidology.  An idea for a 
PICO-T question was subsequently developed.  Would treatment of patients with 
excessively high lipids (probable FH) by a lipid certified NP, improve management, 
when compared to usual care?  The premise was that the NP is specialized in lipid 
management, and that usual care refers to providers taking care of patients with a number 
of medical illnesses and concerns.  Therefore, dedicated treatment to a modifiable risk 
factor would appear plausible, particularly based on the education and role of a doctorally 
prepared nurse practitioner.  Therefore, a formal PICO-T question was developed: In 
non-pregnant adults aged 20 years old or greater, with a diagnosis of probable 
heterozygous familial hypercholesterolemia, would treatment in a lipid clinic by a nurse 
practitioner with a specialty in lipid management, compared to usual care, lead to 
improvement in the LDL cholesterol at the end of a 4 week period?    
Setting 
 The patient selection is from St. Luke’s University Health Network, a large in-
patient and out-patient network, located in eastern Pennsylvania and western New Jersey 
(St. Luke’s University Health Network, 2015).   The Network consists of six hospitals, 
situated over 200 sites in two states.   It has been named one of the top 50 cardiovascular 
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hospitals in the nation, and provides a comprehensive cardiac service line (St. Luke’s 
University Health Network, 2015).  
Population 
Eligible patients were populated from the Clinical Quality Solutions (CQS) 
database, as previously described.  Initially, inclusion criteria were non-pregnant adults, 
greater than 20 years old with an age-related LDL cholesterol cut off of >220, consistent 
with the MED PED criteria (Willams et al., 1993).  Recruitment of the treatment group 
was difficult.  Several patients were contacted, two were scheduled, and then 
subsequently cancelled.  After consulting with lipid experts in the field of lipidology at a 
national lipid conference, reconsideration of the LDL cholesterol cut off criteria was 
performed.  By general expert opinion, the EBP was being based on old criteria, the MED 
PED criteria (Williams, 1993).   In 2001, an LDL cholesterol of >190 was considered 
very high, by the National Cholesterol Education Panel (NCEP) Adult Treatment Panel 
(ATP) III:  
Very high LDL cholesterol (190 mg/dL). Persons with very high LDL 
cholesterol usually have genetic forms of hypercholesterolemia: monogenic 
familial hypercholesterolemia, familial defective apolipoprotein B, and 
polygenic hypercholesterolemia (Third Report of the National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final 
report, 2002, p. 17). 
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Given the most recent guidance from the International FH Foundation (Watts, 
2014), the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol (Stone et 
al., 2014), as well as the NLA FH Recommendations (Goldberg et al., 2011a), the LDL 
cholesterol cut point for this EBP was lowered to >190; rescreening then took place.  
Steps to Implementation 
 There were several steps to consider in the planning phase, including creating a 
project vision, identifying a model of care and communicating regularly and 
collaboratively with information technology (IT).   Notably, early in the planning phase 
of this EBP, a meeting was held with the EHR Director to trial run an acquisition of a 
population of patients with probable FH, without patient identifiers, or provider 
information.  Based on this information, the project seemed feasible.  Further, 
establishing a collaborative relationship with IT, enabled evidence based educational 
material regarding diet, exercise, and medical therapy, to be integrated into a Lipid Care 
Guide through the electronic record.  At the completion of a patient encounter, this 
material could be printed for each patient, enhancing self-management.    
 Working with dieticians and fitness center personnel allowed the integration of 
community services, available at St. Luke’s, into the full treatment algorithm.  The 
process for referrals for medical nutrition therapy was streamlined and free coupon 
vouchers from the St. Luke’s Fitness Centers were offered to promote regular physical 
activity.   Integrating community resources into the treatment is consistent with elements 
of the Chronic Care Model, as suggested by Wagner et al., (2001).  Most notably, 
identifying stakeholders and obtaining administrative support was integral to the 
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development of a new Lipid Clinic, not previously available at St. Luke’s, of which this 
project is a component.  Several cardiology office sites were offered throughout the 
network for clinic visits to accommodate patients’ geographic location and to increase 
patient access to the provider. 
 The CQS program, by Team Praxis, identified through the Allscripts EHR, was 
the data source utilized to determine patient eligibility for both groups.  The prospective 
group, which included patients to be treated by the NP, would emanate from St. Lukes’ 
Cardiology Associates (SLCA), a subsidiary of the St. Luke’s Network, where the NP is 
employed.   Given that the NP functions in a team environment, this method would 
facilitate the informed consent process, while adhering to patient confidentiality, 
consistent with human subject research.  In this fashion, a Pursuit List was queried from 
the Quality database of Allscripts.  From a dropdown selection of the Pursuit List, 
Cardiovascular Disease was selected as a focus.   
The selection criterion was further narrowed by selecting current cardiology 
providers, and excluding the two practicing lipdologists from SLCA.   Columns of 
criteria were chosen to be included in the populated list.  Inclusion criteria were the 
patient name, age, medical record number, attributing provider, and LDL cholesterol.   
From the inputted criteria, a population was created.   The patients could then be sorted 
by populating the LDL in a descending list.  However, at the time of implementation, that 
function was not working properly, therefore a manual search of 213 pages in the 
database was undertaken.  Patients with an LDL-C >190 were obtained, and placed in a 
spreadsheet.    
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A similar approach was undertaken to obtain the comparison group, deselecting 
cardiology providers as inclusion criteria.   The appropriateness of the identified patients 
was then ascertained, first by seeking permission from the patient’s usual cardiologist to 
consider the patient for the EBP.   Communication in this fashion was performed through 
Tasking in the individual patient’s EHR.   Some patients were excluded in this process, as 
not good candidates, per the usual cardiologist.  Other patients were excluded who reside 
In New Jersey, as the provider is not licensed in that state.  All appropriate patients were 
then called by the investigator personally, to invite the patient to participate.   Overall, 
forty-six patients were screened, and 37 patients were contacted.  Patients unable to be 
reached the first time, were phoned at a different time, in the evening, to enhance 
facilitation of successful communication.  Additionally, patients unable to be reached in 
this fashion were mailed a letter.  Therefore, three attempts were made to reach identified 
patients.  Several patients who responded, declined.  Others did not respond at all.   
 Comparison group patients were obtained in a similar fashion, excluding patient 
names, and any identifiers.   Medical record numbers however, were included in order to 
reassess LDL levels in 4-12 weeks for comparison.  Since comparison patients are not 
current SLCA patients, recruitment for a prospective project was not possible, given 
patient confidentiality and the informed consent processes. 
Task List with Time Line- For specific dates of tasks, please see Appendix F. 
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Chapter Six: Evaluation and outcomes 
Data Analysis  
To review, the clinical question the EBP proposed to answer was:  In non-
pregnant adults aged 20 years old or greater, with a diagnosis of probable heterozygous 
familial hypercholesterolemia, would treatment in a lipid clinic by a nurse practitioner 
certified in lipid management, compared to usual care, lead to an improvement in the 
LDL cholesterol at the end of a 3 month period?  An important consideration in 
analyzing the results, is an indicator of provider adherence to the guidelines.  Therefore, 
results will analyzed to reflect provider adherence to rechecking lipids four to twelve 
weeks after initiating statin therapy, to assess for patient safety and adherence, as 
recommended (Stone et al., 2014).  Further, the percent change in LDL-C will be 
assessed, with an ultimate goal, as established in the literature, “for adult FH patients 
(>20 years of age), drug treatment to achieve an LDL cholesterol reduction > 50% should 
be initiated” (Goldberg et al., 2011a, p.136).   
Results 
 In consideration of provider adherence to the guidelines, and in reassessing 
patients’ lipids four to twelve weeks after the initiation of statin therapy, the EBP change 
met this criteria 100% of the time.  Contrastingly, in the comparison group, only 5% of 
the time, were lipids reassessed in four to twelve weeks.  The minimum time frame lipids 
were rechecked after the first assessment, was four months, and the longest was two 
years.  Given, it was assumed that if a provider checked a patient’s lipids, and an LDL 
>190 were obtained, treatment was initiated.  That is not absolutely known, however, but 
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certainly recommended.  Further, to check the lipids and not to initiate therapy, is still not 
consistent with the guidelines.  In summary, provider adherence to the guidelines in the 
comparison group, was strikingly low.  
In the treatment group, four patients were enrolled.  The first patient achieved a 
22% LDL cholesterol (LDL-C) reduction on a non-statin product, over-the-counter red 
rice yeast, along with lifestyle modifications.  Consistent with patient centered care, the 
patient was educated and advised regarding the recommended statin therapy, however the 
patient declined.  A second patient achieved a 55% LDL-C reduction, a third patient, a  
58 % reduction, and the fourth patient, a 39 % reduction, all on conventional statin 
therapy, as well as individualized lifestyle modifications, at four weeks.   In summary, at 
4 weeks 50% of the treatment group met the goal of an LDL-C > 50%.   It is anticipated 
that if the EBP project time frame were extended, one might see additional LDL 
reduction, given the short study period of four weeks.  
 In the comparison group, four of the 20 patients, 20%, had a documented 
reassessment of their lipids, anywhere from four months to two years after the first lipid 
profile was obtained.   One patient’s lipids were reassessed at 12 weeks, within the 
guidelines.  Four of the five patients exceeded the recommended goal, a 50% reduction 
from their baseline LDL-C, while one patient’s LDL cholesterol dropped 3%, over six 
months.  In summary, of the 25% of the comparison patients who had a reassessment of 
their lipids at any time, one patient, .05%,  had a reassessment of lipids within the 
recommended guidelines of four to twelve weeks.   Four patients achieved an appropriate 
level of LDL-C reduction anywhere from four months to two years after the initial lipid 
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assessment.  Given the few number of participants in the treatment group, as well as the 
few numbers of patients who had a reassessment of lipids in the comparison group, 
further statistical analysis between groups is not feasible.   
Relationship of Results to Framework and Objectives 
Results demonstrate a successful treatment strategy, designed to reflect a modern 
care model of a lipid certified NP practicing within a lipid clinic, to treat patients with 
high cholesterol levels.  This strategy is consistent with prior research (Allen et al., 2002; 
Birtcher et al., 2010; Darves 2003; Shafer & Wexler, 1995).  Further, the EBP meets all 
of the elements of the Chronic Care Model (Wagner, 1998a).  These elements include 
self-management, the delivery design as described, decision support by the use of 
evidence based guidelines, and the integration of clinical information services.  
Additionally, the project was supported by the organization’s administration.  
Community resources were offered, such as referrals to medical nutrition therapy and 
physical fitness centers.  Finally, functional and clinical outcomes were measured by a 
percent change in LDL–C.  These indices all reflect the Chronic Care Model.  
“There are probably more than 15 million people with FH worldwide, but less 
than 10% have been detected and only 5% adequately treated” (Watts et al., 2014, 
p.153).  The EBP demonstrates patient centered care, evidence of interdisciplinary team 
work, and evidence based practice, towards the ultimate goals of reducing population 
wide cardiovascular risk as well as individuals’ risk.  It is an example of input 
substitution, where the work of a cost-effective, quality NP can be substituted for the 
work of a physician, who can then be freed up to perform procedures and tasks for which 
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he or she is specifically trained (Bauer, 2010).  Additionally, results demonstrate promise 
as a mechanism to increase patient adherence to therapies, although this was not 
specifically measured.  
Recently, The Institute of Medicine (IOM) formulated a workgroup called the 
Committee on Core Metrics for Better Health at Lower Cost (IOM, 2015).  The work was 
funded by the collaborative efforts of the Robert Wood Johnson Foundation, the Blue 
Shield of California and the California Healthcare Foundation, whose mission was to   
“promote the effectiveness of the measurement enterprise in the United States by 
identifying a parsimonious set of core metrics that deserve widespread implementation 
and to suggest how that implementation might occur” (IOM, 2015, Preface).  
 The recommendations of the Committee have been published by the Institute of 
Medicine and is titled Vital signs: Core metrics for health and health care (IOM, 2015).  
The Committee developed 15 core measures that constitute the vital signs of the health of 
the nation.  Applicable to this EBP project are the following IOM core measures:  (a) 
preventive services, (b) care match with patient centered goals, (c) individual 
engagement, and (d) evidence based care (IOM, 2015).   Further, related priority 
measures have been developed, which include cardiovascular risk reduction.  In the 
future, the use of the core measures may be integrated into the government’s EHR 
incentive program as Meaningful Use metrics and be compared to benchmarked goals, as 
a measurement of preventive care.  As a successful treatment strategy to improve 
patient’s lipids, the EBP is in alignment with the latest IOM recommendations to improve 
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population health, specifically reducing cardiovascular risk, by adhering to guidelines and 
measuring LDL cholesterol reduction.  
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Chapter Seven: Implications for Nursing Practice 
Implications for Nursing Practice 
 The proposed EBP project is consistent with the goals established of a DNP:  
“practice-focused doctoral programs are designed to prepare experts in specialized 
advanced nursing practice” (American Association of Colleges of Nursing, 2006, p.3). 
In addition, it is consistent with the American Association of Colleges of Nursing 
Position Statement established on DNP preparation: to cultivate needed competencies for 
advanced clinical practice, enhance knowledge to improve nursing practice, and to 
prepare advanced practice nurses to provide evidence based care to improve patient 
outcomes (American Association of Colleges of Nursing, 2004).  
Strengths and Limitations 
 There were several limitations of this project.  Initially, the project was designed 
for two groups of patients with probable HeFH, with an age-related LDL cholesterol cut- 
off of a minimum of 220 in the general population ( age >20), based on U.S.MED PED 
criteria, one of the many ways of identifying this cohort clinically.  Patient recruitment, 
however, was difficult.  Many of the patients were already being treated by one of the 
two lipidologists in the practice.  Further, these patients are often young, and working.  
They generally feel well, and may not see the benefit of seeing another provider to treat a 
medical issue that they may not recognize as significant.  Therefore, an adjustment was 
made in the inclusion criteria, with an LDL cholesterol minimum cut-off of > 190, based 
on the guidance from the International FH Foundation (Watts et al., 2014), as well as the 
2013 Guidelines on the Treatment of Blood Cholesterol (Stone et al., 2014) and the 
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National Cholesterol Education Program Adult Treatment Panel III (Third Report of the 
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults, 2002). 
The fact that there are a number of ways of identifying patients with either 
probable, possible, or definitive FH is problematic, in discerning the most appropriate 
criteria for patient recruitment in a project of this sort.  Given this, one might wonder how 
a diagnosis of FH would change treatment.  A diagnosis of FH would suggest cascade 
screening of family members, as it is a genetically transmitted disorder.   Providers then 
could make a more robust impact on population health.  In addition, a diagnosis of FH 
may enhance patient adherence to therapy, as FH is known to increase cardiovascular risk 
and premature heart disease.   Ultimately, a population with an LDL > 190 carries a high 
lifetime cardiovascular risk, constitutes severe hypercholesterolemia and probable FH, 
and therefore should be treated aggressively (Stone et al, 2014, Watts et al., 2014).  
 The time frame of the project was shortened due to an unanticipated late IRB 
approval from Misericordia University, as well as the need to readjust the inclusion 
criteria, and screen for patients a second time.  Due to these issues, the time frame of the 
project was shortened from twelve weeks to four.   Notwithstanding the brevity, based on 
the ACA/AHA Blood Cholesterol Guidelines, it is recommended that one should recheck 
LDL cholesterol levels anywhere from four to twelve weeks after initiating statin therapy, 
to assess for adherence and patient response (Stone et al., 2014).  Therefore, four weeks 
was felt to be an acceptable time period for the treatment group.   
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The current EHR is a limitation.  At the time of patient selection, the Allscripts 
dashboard was not functioning appropriately.  The LDL column could not be populated 
in a descending fashion.  Therefore, patient selection was performed manually, and 213 
pages of patient data were reviewed.   Further, the inpatient and outpatient EHR systems 
do not cross talk.  This makes data collection cumbersome and potentially unreliable.  
 Several scheduling issues were evident.  The timing of the year was a limitation.  
Some patients stated they could not participate because they were traveling to other parts 
of the country for the summer, and would be gone for a number of weeks to months.  
Others found transportation issues difficult, as St. Luke’s encompasses a large geographic 
network, covering six hospitals in two states, and many patients did not desire to travel a 
great distance to be treated.  To ameliorate access issues and enhance patient 
participation, multiple site locations for the project were offered.  
 Overall, patient participation was a significant barrier.  Whether due to feeling 
well, traveling for the summer, noting prior statin intolerance, access issues, or general 
lack of desire, participation was low.   A limitation was the small sample size of the 
treated group.  Perhaps these responses represent the community at large; this may 
contribute to the status of the population’s cardiovascular health, as noted by the CDC 
and U.S. DHHS (CDC, 2014a; U.S. DHHS, 2015).          
 A significant strength of the project is the impact that an NP lipid specialist can 
make on reducing cardiovascular risk.  Results of Cholesterol Treatment Trials (CTT) 
meta-analyses have demonstrated “that each 39mg/dL reduction in LDL-C with statin 
therapy reduced ASCVD events by 22%, and the relative risk reductions in ASCVD 
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events were consistent across the range of LDL-C levels” (Stone et al., 2014, p. 24).   
Therefore LDL cholesterol reduction of this magnitude can positively impact both 
individuals’ lives, as well as improve population health.                    
 The model of team-based care demonstrates strength of the project as well.  
An organizational change in a model of care that has been described cannot be 
undertaken without the support of administration and the department chief.  Further, the 
encouragement from physician colleagues was welcoming and quite supportive.  The 
described EBP, of an NP performing disease management in a lipid clinic is consistent 
with an example of cardiovascular team-based care, as discussed in the 2015 Team-Based 
Care Health Policy Statement by the ACC (Brush et al., 2015). 
Linkage to DNP Essentials 
 Elements of the proposed EBP meet all Eight of the Essentials of Doctoral 
Nursing Practice (AACN, 2006).  The Essentials are listed below, noting how the 
elements were met.  
 I. Scientific Underpinnings for Practice.  The project is evidence based, with a 
scholarly review of the literature and supported by the Chronic Care Model.  
 II. Organizational and Systems Leadership for Quality Improvement and Systems 
Thinking.  The project exhibits an organizational change of care delivery for lipid 
patients. In addition, it showcases an exemplar of team-based care. 
 III. Clinical Scholarship and Analytical Methods for Evidence-Based Practice.  A 
scholarly review and critical appraisal of the literature was performed focusing on 
new knowledge from recent guidelines and recommendations.  
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 IV. Information Systems/Technology and Patient Care Technology for the 
Improvement and Transformation of Health Care.  The project demonstrates 
strong integration of interdisciplinary work with information technology 
integrating evidence from the 2013 Lifestyle Management Guidelines and 
recommendations for treatment of severe hypercholesterolemia and probable 
HeFH into the EHR.  Population samples were derived from a data source through 
the EHR.  
 V. Health Care Policy for Advocacy in Health Care.  The project exhibits 
conformance with the 2015 American College of Cardiology (ACC) Health 
Policy Statement on Cardiovascular Team-Based Care and the Role of Advanced 
Practice Providers (Brush et al., 2015).  As all patient material is available in 
several languages, the project provides a mechanism to decrease health 
disparities.  
 VI. Interprofessional Collaboration for Improving Patient and Population Health 
Outcomes. The project was a culmination of work with stakeholders, 
administration, physician colleagues, dieticians and fitness experts. 
 VII. Clinical Prevention and Population Health for Improving the Nation’s 
Health.  The project demonstrates evidence that an advanced practice nurse can 
improve outcomes, and therefore is capable of improving the cardiovascular risk 
of patients and a population with severe hypercholesterolemia.  As a pilot, it is a 
model for organizational change. 
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 III. Advanced Nursing Practice. The project demonstrates the role of a DNP, 
functioning in an area of specialization, working in an interdisciplinary team, to 
improve the cardiovascular health of individuals and a population with severe 
hypercholesterolemia.  
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Chapter Eight: Summary of Project and Conclusions 
Given that heart disease remains the number one killer of Americans, and 
that hypercholesterolemia, as a known modifiable and treatable risk factor, is 
underdiagnosed and undertreated, the proposed EBP change was examined to 
determine if a nurse practitioner certified in lipid management could improve 
patients’ lipids, over an established time period, compared to care provided by 
non-lipid certified providers.   Familial hypercholesterolemia (FH) affects young 
people with an associated high lifetime cardiovascular risk, therefore, the 
population was selected as a personal choice, as treatment can afford a 
considerable beneficence on patients’ lives, as demonstrated in the literature.   
The EBP change is well supported.  The NLA, as a specialty organization, 
poses several resources for the diagnosis, screening, and treatment of FH, among 
all other dyslipidemias, and is a valuable aide.  Other organizations, such as the 
AHA/ACC and the International FH Foundation, provide similar guideline 
evidence for the diagnosis of FH.  However, the number of ways one can 
characterize a patient as probable, possible, or definite FH can be ambiguous to 
the novice.  As discussed, the National Cholesterol Education Program/ Adult 
Treatment Panel III (NCEP ATP III) in 2001, established that an LDL-C >190 
was consistent with probable FH, and should be aggressively treated as such, to 
decrease one’s lifetime risk for vascular events.  For the purpose of population 
health, this is an accepted cut point for the diagnosis, as reinforced by multiple 
organizations in the literature.  
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Recommended strategies for treatment of FH are well documented.  The 
ACC/AHA provide strong evidence and recommendations for lifestyle 
management for LDL cholesterol reduction, both in terms of diet and exercise.  
Ample evidence exists regarding the benefits of treatment with statins, and more 
recently, ezetimibe (Zetia).  Additionally, the role of an NP managing patients in a 
lipid clinic is in alignment with the role of an advanced practice provider 
functioning as a member of team-based care, as conveyed by the most recent 2015 
ACC Health Policy Statement on Cardiovascular Team-Based Care and the Role 
of Advanced Practice Providers (Brush et al., 2015).  Further, the practice of an 
NP managing patients in a lipid clinic has been established by published literature 
as well.  
Dissemination Plans 
This EBP will be disseminated by presentation to a population of 
cardiovascular nurses, as well as other interested healthcare personnel, at a 
hospital network cardiovascular symposium in the fall of 2015.  It will also be 
presented at a cardiovascular educational meeting, attended by cardiologists, 
fellows, residents and advanced practice providers.   Further, it may be submitted 
to The Journal of Cardiovascular Nursing, which is the official journal of the 
Preventive Cardiovascular Nurses Association  (PCNA), either as a model of a 
pilot, or as a presentation of 4 patient case studies.  Alternatively, and more likely, 
however, the EBP will be continued, as an organizational change as described in 
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the next section, with additional data collection and subsequent delayed 
submission for publication.  
Future ideas or next steps related to project 
As an organizational change, the EBP will be continued.  This process has 
had the support of both administration as well as the Department Chief.   Pending 
submission and acceptance of a new IRB application to St. Luke’s IRB, additional 
patients will be recruited and data will be collected, to assess effects of 
implementing the change on a more widespread level.  Given the nature of the 
Network’s geographic location of over eight counties and 60 miles, the hours and 
location of the Lipid Clinic will be expanded to additional sites.  Increasing 
provider access and clinic hours will facilitate additional patient recruitment for 
the project.   Further, Network cardiologists will be reeducated about the 
availability of the Clinic, the expanded hours, and additional site offerings, to 
increase in-house referrals and patient recruitment of this population.    
Results also demonstrate a need for provider education to enhance 
adherence to evidence based practice and implementation of the guidelines.  The 
difficulty in patient recruitment likely represents an area for additional patient 
education as well, to reinforce the high lifetime cardiovascular risk that FH 
patients carry, and to reiterate the need for early and aggressive treatment.  
Additionally, results infer a need to increase FH awareness globally, which has 
been advocated for by the NLA.  
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Developed by The MacColl Institute, © ACP-ASIM Journals and Books, reprinted with 
permission from the American College of Physicians.  
Published by Wagner, E. H. (1998b), in Chronic disease management: what will it take to 
improve care for chronic illness? Effective Clinical Practice: ECP, 1(1), 2-4. 
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Appendix B 
From: Murtaugh, Holly  
Sent: Monday, February 16, 2015 9:00 AM 
To: Weidner, Carla 
Subject: FW: Documents have been IRB reviewed: SLHN 2015-10 IRB No.: SLHN 
2015-10 
Please see below.  The IRB study you submitted titled “Lipid Management of Patients 
with Probable Familail Hyperlipidemia” (SLHN # 2015-10) was reviewed and deemed 
exempt from IRB Review. 
**Please note this is the only notification you will receive from the IRB Office regarding 
this study ** 
From: do_not_reply@ddots.com [mailto:do_not_reply@ddots.com]  
Sent: Tuesday, February 10, 2015 3:38 PM 
To: Murtaugh, Holly 
Subject: Documents have been IRB reviewed: SLHN 2015-10 IRB No.: SLHN 2015-10 
 
An event for Protocol SLHN 2015-10 has been marked as having completed review. 
Local ID: SLHN 2015-10 
Protocol: SLHN 2015-10 
Type of Submission: New Studies 
IRB Meeting Date: 03/03/2015 
Action: Not Approved 
Reviewed By: Exempt 
Action Date: 02/10/2015 
Agenda: new study - IRB Exemption 
 
Studies involving prospective data collection are not exempt. Please revise study dates 
and re-submit as retrospective, or submit as prospective for full board review. Full board 
review will require different submission form. 
 
List Documents and Comments for each Document:  
Download File: slhn 2015-10 - application & exempt request form.pdf 
Download File: slhn 2015-10 - article and cvs.pdf  
Download File: slhn 2015-10 - icf form.pdf  
Download File: slhn 2015-10 - protocol.pdf  
 
Review Completed By: Stawicki, Stanislaw P. 
Completed Date: 02/10/2015  
------------------------------ 
Email sent to: Murtaugh, Holly; Pytlewski DO, Gerald Confidentiality Notice: This e-
mail message, including any attachments, is for the sole use of intended recipient(s) and 
may contain confidential and privileged information. Any unauthorized review, use, 
disclosure or distribution is prohibited. If you are not the intended recipient, please 
contact the sender by reply e-mail and destroy all copies of the original message. 
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StLuke\s 
UNIVERSITY HEA TH NETWORK 
Stanislaw P. Stawicki, M.D., F.A.C.S. 
Chair, Department of Research & Innovation 
Medical Director, Institutional Review Board 
Associate Professor, Temple University School of Medicine 
NW2 Admin ., 801 Ostrum Street, Bethlehem, PA 18015 
 
 
DEPARTMENT OF RESEARCH & I N NOVATION 
 
January 23, 2015 
 
 
 
 
 
 
To Whom It May Concern, 
 
This letter is in support of a Misericordia University Doctoral Research Project proposed by Ms 
Carla Weidner. The project's title is Lipid Management of Patients with Familial 
Hypercholesterolemia by a Nurse Practitioner. 
 
Ms Weidner is well qualified to conduct the proposed project, and has formed a research team 
that includes one of the foremost area experts in the field of lipidology, Dr. Gerald Pytlewski. 
 
I recommend, without reservations, that the project be considered favorably by  the Misericordia 
University Doctorate of Nursing Practice (DNP} faculty. Please do not hesitate to contact me 
with any questions or concerns. 
 
Sincerely, 
<::: be>·-- ====:::==:::> 
Stanislaw P. Stawicki, M.D., F.A.C.S. Chair, 
Department of Research & Innovation Medical 
Director, Institutional Review Board 
Associate Professor, Temple University School of Medicine NW2 
Administration 
801 Ostrum Street 
Bethlehem, PA 18015 
Phone (484) 526-4426 
Email:   stanislaw.stawicki@sluhn.org 
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MISERICORDIA  
    UNIVERSITY. 
May  13, 2015 
  
Carla Weidner, MSN  
Brenda Hage, Ph.D. Nursing Department Misericordia University Dallas, PA   18612 
 
Dear Ms. Weidner and Dr.  Hage: 
 
Thank you for submitting the modifications to your IRB application, Lipid Management of 
Patients with Probable Familial  Hypercholesterolemia  by a Nurse Practitioner,  number 
13-15-Tl . Your study is now approved by the IRB. 
 
As part of the approval, the IRB has received and accepted the consent form as submitted. The 
attached consent form with a valid period of eligibility is the only consent form to be used. Any 
modifications must be approved by the IRB. The date stamp indicates the eligible period. 
 
You will be reminded  one month prior from the expiration date of your research   protocol to 
complete an End-of-Project Report. You also have the responsibility to notify the IRB of any 
changes in the conduct of this study or injury to study subjects and to retain all approved 
application documents and signed consent forms for a minimum of three years following 
completion of the study (this includes student research). Please refer to the IRB Policies and 
Procedures  document for specific details on what is   expected. 
 
Ifyou have any questions, please feel free to contact me. Sincerely, 
 
 
 
McKinley H. Manasco, Ph.D. Chairperson, IRB 
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St. Luke’s University Health Network 
 
 
Department: Cardiology        
 
Principal Investigator: Carla Weidner, MSN CRNP      Telephone: 484-503-0600  
 
Co-Investigator(s): Gerald Pytlewski DO       Telephone: 610- 435-5913  
 
Medical Title: Lipid Management of Patients with Probable Familial 
Hypercholesterolemia by a  Nurse 
Practitioner______________________________________________________________                
 
Lay Title: Lipid Management of Patients with High Cholesterol by a Nurse Practitioner 
Sponsor: Misericorda University 
 
You are being asked to take part in a medical research study. As required by federal 
regulations, this research study has been reviewed and approved by an Institutional Review 
Board (IRB), a committee that reviews, approves and monitors research involving humans. 
Before you can make a decision about whether to participate, you should understand the 
possible risks and benefits related to this study. This process of learning and thinking about 
a study before you make a decision is known as informed consent and includes: 
 Receiving detailed information about this research study; 
 Being asked to read, sign and date this consent form, once you understand the study 
and have decided to participate. If you don’t understand something about the study 
or if you have questions, you should ask for an explanation before signing this form; 
 Being given a copy of the signed and dated consent form to keep for your own 
records. 
 
Study Purpose and Procedures 
 
You are being asked to participate in this clinical research study by donating a sample of 
your blood.  The blood sample will be used for the following:  
 
Purpose of the Study:  
Significantly elevated blood cholesterol levels can be hereditary, and is one of the risk 
factors for  
Hardening of the arteries, or atherosclerosis.   Untreated, or inadequately treated blood 
cholesterol can promote the formation of heart disease.  National agencies have done 
studies indicating there are a lot of people with cholesterol numbers that are too high. 
Strategies to improve people’s blood cholesterol have been explored.  This study will 
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compare patient’s blood cholesterol treated by a nurse practitioner to patient’s blood 
cholesterol treated by their usual provider, or doctor.  
 
Description of the Study: 
Patients who obtain blood work at any St. Luke’s network facility review and sign a 
General Consent form prior to their blood being drawn.  Line item 3 reads:   
 I authorize the facility to use and disclose my health information: (1) to other health care 
professionals who are involved in my treatment, either now or in the future. 
Within the realm of this permission, it has been identified that the blood work you 
recently had drawn showed blood cholesterol levels that were elevated.  
 
In this study, there will be 2 groups of 20 patients each. One group will be cared for 
by their usual provider, or doctor.  The other will be cared for by me, a nurse 
practitioner. Each group will receive the same standard care that is available for 
patients with high cholesterol. At the end of 12 weeks, all patients will have their 
fasting blood cholesterol levels rechecked, which is a part of the routine standard 
care. A comparison will be made in the percent change from baseline to 12 weeks. 
No other data will be collected or examined.  
 
 
You have been told that, as a participant in this study, you will have blood drawn. The 
amount of blood drawn will be about one teaspoon.   
 
You will be in this study for two blood draws over a period of 12 weeks.   
 
What Are the Risks of Drawing Blood? 
 
You have been told that certain risks may be associated with the drawing of blood. The 
known risks are discomfort as the needle is inserted, bleeding, bruising and discoloration 
around the site of the blood draw, infection at the site, and, rarely, fainting.  Risks will be 
minimized by having the blood drawn by an individual who is trained to perform this 
procedure. 
 
Are there benefits to me for being in this study? 
 
You will not personally benefit from taking part in this study.  However, the information 
gained may be of benefit to society in general or to certain individuals in the future. 
 
Confidentiality 
 
Care will be taken to preserve confidentiality of all protected health information (PHI) 
collected about you during the course of this study. PHI is information such as your name, 
address, social security number and any other information that could identify you 
personally. PHI that is collected for this study may be reviewed by the researchers at St. 
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Luke’s University Health Network who are conducting this study, the Institutional Review 
Board (IRB), and appropriate offices of St. Luke’s University Health Network. You are 
also allowing the research team to share your PHI with your health insurance company (if 
necessary for billing for standard medical care).  
 
In addition, the following organizations or individuals may request and will be given access 
to your PHI:  None 
 
 
Certain information about you and your blood will be kept in the study records. 
This includes the following: 
            Cholesterol numbers 
 
 
 
 
 
 
 Identifiers will not be maintained with this data, and there will be no way to 
link it to you. 
 
This information will be kept in a locked filing cabinet or password-protected computer 
database, and only the investigator and his or her research team will have access to this 
information. This information will be kept indefinitely. 
 
The information from this study may be published in scientific journals or presented at 
scientific meetings but you will not be personally identified in these publications and 
presentations. 
 
You will not be told of the research results obtained using your blood sample unless the 
research tells us important information about your health. In this case, we will ask for your 
permission to inform your personal physician. You will be asked to sign a separate 
authorization for this. 
 
You may revoke this authorization to use and share your PHI at any time by contacting 
the principal investigator, in writing, at: weidnerc@misericordia.edu or Carla Weidner 
NP, St. Luke’s Cardiology, 1700 Riverside Circle, Suite 301, Easton, PA 18045 
 
If you revoke this authorization, you will no longer be able to participate in this research 
study, and the future sharing of PHI will be stopped.  However, the PHI that has already 
been collected and shared may still be used. 
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Will I be Paid for Being in the Study? 
 
You will not be paid for your blood sample. 
 
In addition, you will not be paid if inventions and/or patents are developed from the blood 
you provide for this study or the study results. 
 
What is my Alternative to Participation? 
 
This study does not involve treatment, and provides no benefit to you. Your alternative is 
not to participate in this study. 
 
Will I be told about any new findings?  
 
Anything learned during the study, beneficial or not, that may affect your health or your 
willingness to continue in the study, will be told to you and explained.  
 
Who Should I Contact if I Have Any Questions or Concerns?  
 
If you have questions related to your rights as a participant in a research study, you may 
call the St. Luke’s University Health Network Institutional Review Board (IRB) at 570-
674-1483. 
 
If you have any questions about the study, or problems or if you feel you have experienced 
a research-related injury as a result of being in this study, you may call Carla Weidner NP 
at 484-526-0600 or Dr. Pytlewski at 610- 435-5913. 
 
In the event that you experience a research-related injury, comprehensive medical and/or 
surgical care (including hospitalization) to the extent needed and available will be provided. 
However, St. Luke’s University Health Network cannot assure that this comprehensive 
medical and/or surgical care will be provided without charge. The costs will be billed to 
your insurance carrier but they may ultimately be your responsibility. A research-related 
injury is a physical injury or illness resulting to you as a direct result of the experiments, 
treatment(s) and/or procedure(s) used in this study that are different from the medical 
treatment you would have received if you had not participated in this study.  
 
Are There Costs to me for being in this Study? 
 
There is no cost to you for participating in this research. If you receive a bill that you think 
is wrong, please discuss it with the study investigator/clinician or coordinator. 
 
Voluntary Consent and Subject Withdrawal 
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You voluntarily consent to be in this study by providing a sample of your blood.  You have 
been told of the possible risks that might occur, and you are aware that you will not benefit 
from your participation in this study.  
 
You may refuse to participate in this investigation, and this will not affect your future 
medical care at St. Luke’s University Health Network. 
 
You may discontinue study participation without penalty or loss of benefits to which you 
are otherwise entitled and without affecting your future care at St. Luke’s University Health 
Network. 
 
By your agreement/your permission to participate/ in this study, and by signing this 
consent form, you are not waiving any of your legal rights. 
 
You affirm that you have read this consent form. You have been told that you will 
receive a copy. 
 
         
Your Name (please print or type)     
 
     ____________   
Your Signature   Date     
 
 
      
Name of Person Conducting    
Consent    
 
     _____________ 
Signature of Person Conducting  Date 
Consent  
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Appendix F 
Task List Timeline 
Project component                                                                               Date of completion 
Developed an evidence based practice (EBP) vision and identified a mentor           9/8/14                                          
Site visit with a Lipid Clinic in Berkely Heights, N.J.                                             9/25/14 
Administrative Strategic Planning meeting for the Lipid Clinic                             10/17/14 
Initial meeting with staff from electronic health records (EHR); discuss population     
         screening and plans for integrating educational materials into EHR          10/18/14                                             
 Submitted a final PICO-T question                                                                        10/18/14  
Administrative Strategic Planning meeting for the Lipid Clinic                             10/22/14 
Identified patient educational material to be incorporated into the EHR                10/23/14 
Completed the NIH program “Protecting Human Research Participants”  
and obtained a certificate of completion.                                                      11/4/14                                                                       
Met with Network Service Line Administrator and Supervisor of EHR to discuss  
     integration of patient education materials into a Lipid Care Guide             11/12/14 
Submitted final table of evidence /literature review to support the PICO-T           11/15/14 
Met with Supervisor of the EHR to discuss implementation of the Lipid Clinic  
    Care Guide and to again discuss EHR screening of the EBP population    11/21/14                           
Received formal letter of support from St. Luke's Network for EBP                        1/23/15                      
Submitted Chapter I: Introduction                                                                               2/2/15                                                                         
Obtained signature support from key stakeholders for IRB submission                     2/6/15 
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Received IRB approval from St. Luke’s University Health Network                      2/16/15                                                                                     
Submitted Chapter II: Review of the Evidence                                                         2/22/15       
Attended St. Luke’s Network EHR workshop                                                            3/2/15                                                                                      
Submitted Chapter III: Organizational Framework                                                    3/3/15                                                         
Received IRB approval from Misericordia University                                              5/13/15    
Accessed the CQS Quality Dashboard through the EHR, to ascertain a  
    comparison group of patients                                                                         5/27/15                                                                                               
Continued to seek eligible patients for the EBP                                 process began 6/01/15 
Submitted Chapter IV: Project Design                                                                      5/31/15 
Submitted Chapter V:  Implementation Procedures and Processes                           6/10/15 
Planned implementation of the practice change                                                        6/24/15                                          
Submitted Chapter VI: Evaluation and Data Analysis                                              7/24/15 
Submitted Chapter VII: Implications for Nursing Practice, Strengths                       
  and Limitations and Applicability to the Eight DNP Essentials                   6/22/15 
Project end                                                                                                                 7/31/15                                                                                                                                                                                                                    
Measure clinical outcomes                                                                                        7/23/15                                                                                       
 Analyze outcomes                                                                                                    7/23/15 
Submitted Chapter VIII:  Summary and Plan for Dissemination                              7/28/15 
 
 
 
 
